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ABSTRACT OF DISSERTATION
 
 
 
POLYAMINE MODULATION IN ALCOHOLISM: EXAMINATION USING A 
NOVEL SCREENING PROCEDURE DESIGNED TO PREDICT ANTI-RELAPSE 
AND NEUROPROTECTIVE EFFICACY 
 
Alcohol dependence is a major public health concern. Despite the FDA’s approval 
of multiple anti-relapse drugs, relapse rates remain unacceptably high. Furthermore, 
cognitive deficits among chronic drinkers are evident and are suggested to contribute to 
relapse risk. Current evidence suggests that several critical features of alcoholism and 
alcohol-associated neurodegeneration are mechanistically linked to glutamatergic actions; 
specifically, they appear positively affected by glutamatergic inhibition, particularly 
inhibition via polyamine modulation of a subpopulation of n-methyl-d-aspartate 
receptors. The current project was designed to evaluate the performance of two putative 
polyamine modulators (JR-220 and CP-101,606) in a variety of screens designed to 
identify the potential to reduce withdrawal severity, neurotoxicity and relapse risk. 
Screens included a complex organotypic screen designed to assess neuroprotective 
potential (Experiment 1), a simple behavioral screen designed to assess withdrawal 
severity (Experiment 2) as well as several more complex behavioral screens designed to 
examine cue-conditioning during withdrawal (Experiment 3), relapse behavior 
(Experiment 4), stress-associated consumption (Experiment 5) and binge-like 
consumption (Experiment 6). An additional open field experiment (Experiment 7) was 
conducted in order to address interpretational issues concerning activity in Experiments 
2-6. Finally, as a first step in moving beyond simple screening, we expanded our binge 
screen to adhere more closely to an established, validated model of binge consumption 
(Experiment 8). While some interpretational issues were noted, taken together, the results 
from these experiments provide strong evidence for both drugs as potential 
pharmacotherapies for alcoholism and further implicate polyamines and NR2B subunits 
as critical mechanisms in ETOH consumption and withdrawal. 
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Chapter 1. Introduction 
 Alcohol dependence is a major public health concern, with an estimated annual 
economic cost of over $180 billion (Harwood, 2000; NIAAA, 2004; Lupton, Burd & 
Harwood, 2004). In the US, alcohol dependence ranks 3rd in preventable mortality 
(DHHS, 2000), is estimated to affect approximately 4% of the population (Grant et al., 
2004), and contributes to more than 100,000 deaths, annually (McGinnis & Foege, 1999). 
 
Alcohol dependence, herein referred to as alcoholism, is a chronic, relapsing 
disorder with numerous detrimental health consequences. DSM-IV characterization of 
dependence includes frequent intoxication, compulsion to consume alcohol, tolerance, 
loss of control in limiting consumption despite adverse consequences and emergence of a 
negative emotional state during withdrawal (American Psychiatric Association [DSM-IV-
TR], 2000). The DSM-IV recognizes both alcohol dependence and abuse as alcohol use 
disorders (AUDs), however alcohol abuse diagnoses are reserved primarily for 
individuals not reaching criteria for dependence, but who drink despite alcohol-related 
problems, or drink in dangerous situations (e.g., driving). Alcohol abuse was the most 
common problem treated in substance abuse treatment centers from 1994-1999, with 18.2 
million people in the US meeting AUD criteria (SAMHSA, 2008). 
 
 Ethanol (C2H5OH; ETOH), also referred to as ethyl or grain alcohol, is a small 
straight-chain molecule, and the intoxicating component in alcoholic beverages. Evidence 
for human ETOH consumption has been noted as far back as the Neolithic period 
(McGovern et al., 2004), and its contemporary consumption across cultures is nearly 
ubiquitous. Ethanol is considered a central nervous system (CNS) depressant and 
psychoactive drug. Dosage is quantified as blood alcohol content (BAC), either as mg/dl, 
or as % v/v. 
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 Due to the aforementioned economic and health concerns, the development and 
identification of efficacious treatments for alcoholism remain primary goals in basic 
research. The current work is focused on the identification and development of known 
and novel compounds, examining their potential efficacy as neuroprotective and anti-
relapse agents. 
 
1.1 Subjective Effects 
 ETOH has a wide array of subjective effects, dependent on individual differences, 
dose, and expectations (Sher et al., 2005), which can be generally characterized as 
anxiolytic, disinhibitive and euphorigenic. Paradoxically, while considered a CNS 
depressant, ETOH possesses strong stimulatory properties, particularly at lower doses, 
and during the ascending limb of the BAC curve. At lower doses (.02-.05 mg/dl BAC), 
ETOH produces feelings of “warmth” and relaxation. Moderate doses (.05-.09 BAC) are 
associated with reduced inhibitory control, euphoria and mild psychomotor perturbances. 
Higher doses (.1-.19 BAC) are associated with ataxia, confusion, mood disturbances and 
drowsiness, with still higher doses inducing amnesia, unconsciousness, respiratory 
distress and death, with an LD50 of approximately .4 (for review see Doweiko, 2010). 
 
1.2 Absorption 
 Ethanol is both water and lipid soluble, facilitating its rapid distribution to all 
blood-rich tissues in the body. Due to its high water solubility, concentrations in brain 
quickly surpass those in blood, (Kranzler & Ciraulo, 2005). The small intestine provides 
the main route of ETOH absorption, however 10-25% of absorption occurs via stomach 
lining (Kaplan, Sadock & Grebb, 1994). Ethanol is detectable in blood within one minute 
following consumption (Rose, 1988), with its rate of absorption primarily dependent on 
the presence of food, which limit alcohol’s ability to diffuse through the stomach lining 
and intestinal walls (Sher et al., 2005; for review see Doweiko, 2010). 
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1.3 Metabolism & Excretion 
 The primary metabolism of ETOH occurs in liver via several isoenzymes of alcohol 
dehydrogenase (ADH). There are five classes of ADH (1-5), but the hepatic form (in 
humans) is primarily Class 1, and is found in stomach and liver. ADH catalyzes the 
oxidation of ETOH to acetaldehyde by converting NAD+ to NADH.  A secondary 
mechanism of ETOH metabolism is the microsomal ethanol oxidizing system (for review 
see Lieber, 1999). This system involves metabolism by cytochrome P450, particularly 
CYP2E1 (Koop, 2006; Lieber, 2004), also producing acetaldehyde. Acetaldehyde is 
unstable, forming free radical structures (discussed in greater depth below) and prolonged 
acetaldehyde exposure in liver and kidneys is a major health concern in chronic 
alcoholics. Acetaldehyde is converted to acetic acid by acetaldehyde dehydrogenase. 
Acetic acid may be excreted in urine, or further reduced to Acetyl-CoA by Acetyl-CoA 
Synthetase. Acetyl-CoA can then enter the citric acid cycle, where it is converted to CO2 
and H2O (for review see Holford et al., 1987). 90-95% of ETOH elimination in humans is 
accounted for by oxidation, with excretion via skin, lungs and kidneys accounting for the 
remainder (Holford, 1987). 
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Chapter 2. Pharmacology 
 In the 1960s, the study of ETOH interactions with ion channels was initiated with 
the discovery of its suppressant effect on sodium and potassium currents in squid axons 
(Armstrong & Binstock, 1964; Moore, Ulbricht & Takata, 1964). Since that time, it is 
difficult to name a receptor/transmitter system whose interaction with ETOH has not 
been examined. While a complete review of these interactions is beyond the scope of the 
current work, ETOH effects on a number of neurotransmitter systems, with attention to 
neuropharmacology thought to relate to its neurotoxic and/or reinforcing effects, will be 
discussed. 
 
2.1 ETOH & Dopamine 
 Although a number of transmitter systems and brain structures contribute to 
ETOH’s reinforcing action, alterations in mesolimbic dopamine (DA) is a common 
downstream effect. This system is comprised of DAergic projections extending from the 
ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAcc). 
Systemic ETOH injections increase extracellular DA in rodent NAcc (e.g., Blomqvist, 
Engel & Nissbrandt, 1993; Diana, Pistis & Carboni, 1993; Di Chiara & Imperato, 1985), 
as does voluntary ETOH consumption (Howard et al., 2008), with DA and BAC levels 
highly correlated. Additionally, DA increases in human ventral striatum following ETOH 
administration, which correlate with subjective euphoria, have been reported (Boileau, et 
al., 2003). That mesolimbic DA is involved in ETOH reinforcement is supported by 
reductions in ETOH self-administration following DA antagonism in NAcc (Rassnick, 
Pulvirenti & Koob, 1992). Activation of mesolimbic circuitry is induced by a number of 
ETOH effects, including interaction with glutamate (GLU), nicotinic acetylcholine 
(nACh), opiate, serotonin (5-HT) receptors, and gamma-aminobutyric acid (GABA) 
receptors (for review see Vengeliene, 2009). 
 
 However, while mesolimbic DA activation is necessary for the reinforcing 
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properties of many drugs of abuse, ablation of mesolimbic and nigrostriatal systems does 
not abolish ETOH consumption in rodents (Kiianmaa et al., 1979; Shoemaker et al., 
2002). Similarly, selective ablation of NAcc fails to disrupt consumption in both 
heterogenous (Fahlke et al., 1994; Myers & Quarfordt, 1991) and alcohol preferring 
(Ikemoto et al., 1997; Koistinen et al, 2001) rats. These findings do not suggest that 
ethanol’s activation of DAergic systems is unimportant, but rather highlight the varied 
contribution of numerous systems to consummatory behavior (for review see Gonzales, 
Job & Doyon, 2004), in a manner which seems somewhat unique relative to other 
substances of abuse. 
 
2.2 ETOH & 5-HT 
 ETOH potentiates 5-HT receptor function (Lovinger & Zhou, 1994) and increases 
5-HT at numerous nuclei throughout brain (McBride et al., 1993; LeMarquand et al., 
1994; for review see Kirby et al., 2011). 5-HT is known to interact with DAergic 
systems, modulating mesolimbic DA output. While this interaction is not well 
understood, microdialysis studies suggest that 5-HT exposure in the NAcc and striatum 
stimulate DA release (Kelland & Chiodo, 1996). Direct synaptic contact between 5-HT 
terminals and DA cells in the midbrain supports such an interaction, and provide an 
additional mechanism through which ETOH is suggested to exert a reinforcing effect. 
However, while it is clear that altering 5-HT function can modulate ETOH self-
administration, contrasting findings in the literature somewhat obscure the mechanistic 
contributions to this interaction; increasing 5-HT bioavailability appears to reduce ETOH 
intake (Fadda et al., 1991; Hodge et al., 1993), although 5-HTr antagonism of several 
receptor subtypes, including 5-HT3 and 5-HT2, also reduces intake (Roberts et al., 1998). 
 
2.3 ETOH & Opiate Systems 
 The opioid receptor system is composed of metabotropic receptors of at least three 
types (μ, δ, κ). Endogenous opioid peptides are known to play a role in the rewarding 
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effects of several drugs of abuse, primarily (though not exclusively) through their 
modulation of mesolimbic DAergic activity, although such action appears generally 
limited to peptides activating the μ and δ receptors. It is now clear that significant 
interaction with the opioid system occurs following ETOH exposure (for review see 
Hertz, 1997), however the details of much of this interaction remain equivocal. ETOH 
appears to increase the density of both μ and δ receptors in animal models (Charness et 
al., 1993; for review see Tabakoff et al., 1996). Low to moderate concentrations of 
ETOH increase the release of the endogenous μ receptor agonist, beta endorphin, in the 
VTA (Jarjour, Bai & Gianoulakis, 2009). Such findings provide another mechanism 
through which ETOH exerts reinforcing effects, as activation of VTA-associated μ 
receptors enhances DA efflux in NAcc. Additionally, powerful evidence for the 
significance of ETOH’s interaction with this system has been elucidated via opioid-
specific pharmacological manipulation (reviewed below). 
 
2.4 ETOH & Acetylcholine 
 ETOH alters the function of neuronal nicotinic acetylcholine receptors (nAChRs). 
ETOH enhances the response to nicotine in vivo (Breese et al., 1993) and appears to 
interact directly with nAChRs (Aistrup et al., 1999); it is suggested to act as a co-agonist 
to ACh at some receptor subtypes, and may function allosterically, increasing agonist 
affinity for the receptor (Forman, Righi & Miller, 1989). For example, ETOH increases 
responsiveness to nicotine in α2b2, α3b2, and α4b2 receptor subtypes (de Fiebre, Papke 
& Meyer, 1995), and potentiates inward currents at α3b4 nAChR subtypes. ACh agonism 
in VTA stimulates DA release in NAcc (Li et al., 2008) providing a possible mechanism 
of ACh-dependent ETOH reinforcement. However, inhibitory effects have also been 
noted (e.g., Covernton & Connolly, 1997), highlighting the complexity of ETOH-nAChR 
interactions. Of particular interest, ETOH has been shown to inhibit α7 nAChR subtypes 
(e.g., de Fiebre & de Fiebre 2005; Narahashi et al., 1999), with further examinations 
suggesting that this α7 subtype is particularly important in modulating several behavioral 
and physiological responses to ETOH (Bowers et al., 2005). Additional evidence for 
7 
 
 
cholinergic involvement is provided by nAChR antagonists, which attenuate 
consummatory responses in a variety of models and species (e.g., Ericson et al., 1998; 
Blomqvist et al. 1996).  
 
2.5 ETOH & GABA 
 GABA is the major inhibitory neurotransmitter in mammalian CNS. ETOH 
allosterically modulates the ionotropic GABA-A receptor complex and potentiates 
chloride flux through the membrane, resulting in hyperpolarization produced by GABA. 
Many behavioral effects of ETOH mimic those of GABA-A receptor agonists, suggesting 
the direct involvement of GABA-A receptors in its action. GABA-A receptors are co-
localized on DA neurons and GABAergic interneurons in VTA (Xi & Stein, 1998), 
facilitating a close interaction between these systems, with mesolimbic DA release 
regulated by GABA interneurons (Maldonado et al., 1997). Inhibition of these 
interneurons, thought to occur following ETOH exposure, increases NAcc DA release 
(Kalivas et al., 1990). GABA appears involved in ETOH’s behavioral effects (e.g., 
ataxia, anesthesia), as GABA-mimetics enhance ETOH-associated behaviors, whereas 
functional antagonists decrease them (for review see Deitrich et al., 1989). Interestingly, 
such GABA antagonists also appear to reduce consummatory behaviors (Lister & 
Linnoila, 1991; Mihic & Harris, 1996; for review see Grobin et al., 1998). While these 
findings provide only surface detail concerning the interactions of ETOH in the GABA 
system, ample evidence suggests GABA receptor subunit composition and concentration 
of ETOH in the system can alter such interactions in a complex manner (for review see 
Lobo & Harris, 2008). 
 
2.6 ETOH & Glutamate 
 Glutamate is the major excitatory transmitter in the mammalian brain. To date, 
three groups of G-protein coupled metabotropic GLU receptors (mGluRs) have been 
identified; Group I (mGluR1 & mGluR5) activates phospholipase C, producing 
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diacylglycerol and inositol triphosphate as secondary messengers, while Groups II 
(mGluR2 & mGluR3) and III (mGluR4, mGluR6, mGluR7 & mGluR8) are negatively 
coupled to adenylyl cyclase. The mGluRs are responsible for slow glutamate-mediated 
neurotransmission and modulation of transmitter release. They couple with G-proteins 
and are located throughout the limbic and cortical brain regions implicated in alcoholism, 
and in particular, group I mGluRs (mGluR1 and mGluR5) appear important in regulating 
the effects of drugs of abuse (Kenny & Markou, 2004).  
 
 While mGluRs are almost undoubtedly involved in ETOH action, the ionotropic 
GLUrs have received far more attention; three basic receptors families have been 
identified, including the N-methyl-D-aspartate receptor (NMDAr), the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAr) and the kainic acid 
receptor (KAr). All three are tetrameric complexes, and are inhibited by ETOH at 
physiologically relevant concentrations (Lovinger et al., 1989; Weiner, Dunwiddie & 
Valenzuela, 1999; Simson et al., 1991). Fast synaptic transmission within this system is 
mediated by AMPAr & KAr, while NMDArs appear to mediate slower synaptic kinetics, 
involving Ca2+ and Ka+ flux (for review see Hoffman, 2003). 
 
 AMPA receptors are composed of subunits GLUr1-4, which all contain a GLU 
binding site. AMPAr are generally permeable to Ca2+, Na+ and K+, although many 
contain the Ca2+-impermeable GLUr2 subunit. ETOH inhibition of AMPArs is well noted 
(Dildy-Mayfield & Harris, 1992; Lovinger, 1993a; Wirkner et al., 2000) and occurs at a 
wide range of concentrations (10-100mM). AMPAr undergo strong desensitization 
following agonist exposure (Trussell et al., 1988; Tang et al., 1989), although comparably 
weaker and more rapid desensitization following AMPA or GLU exposure (Tang et al., 
1989; Trussell & Fischbach, 1989; Hestrin, 1992; Barbour et al., 1994). Emerging 
evidence suggests that ETOH inhibits AMPArs by stabilizing this desensitized state 
(Moykkynen et al., 2009). Such inhibition is thought to be noncompetitive, distinct from 
channel blockade (Peoples et al., 1997; Wirkner et al., 2000), although interestingly, 
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AMPAr do not appear to undergo adaptation following chronic ETOH (for review see 
Davis & Wu, 2001). 
 
 KA receptors are composed of subunits GLUr5-7 and KA1-2, and can form 
homomeric (GLUr only) or heterometric (GLUr5 and KA1-2) stoichiometries (for review 
see Dingledine et al., 1999). While initial reports indicated preferential sensitivity of 
NMDAr to ETOH, compared to AMPA/KAr (Hoffman et al., 1989; Lovinger et al., 
1989), such sensitivity appears to rely heavily on receptor localization. For instance, KAr 
in hippocampal CA3 neurons appear strongly affected by ETOH exposure (Weiner, 
Dunwiddie & Valenzuela, 1999). Postsynaptic KArs appear to share a primary cellular 
function with AMPArs, both enabling the voltage-dependent functioning of the NMDAr. 
 
2.6.1 NMDAr 
 The NMDArs are critically involved in the synaptic plasticity associated with 
neuronal development, learning & memory (Collingridge & Singer, 1990; Collingridge & 
Lester, 1989). It is generally agreed (see Hawkins et al., 1999; Premkumar & Auerback; 
1997 for evidence to the contrary) that they are constructed as tetrameric ligand-gated 
cation channels, composed of two NR1 and two NR2 subunits (McBain & Mayer, 1994; 
Schorge and Colquhoun 2003). Although recent findings have also identified NR3 
subunits, these appear to render receptors insensitive to GLU or NMDA and may 
assemble with NR1 subunits to form excitatory glycine receptors (Chatterton et al., 
2002), however will not be discussed here. The receptor contains six major binding 
domains. The GLU binding site, which also binds NMDA, is located on NR2 subunits; 
the Mg2+ binding site is located within the channel, which it blocks under resting 
conditions; the MK-801 binding site, which binds other phencyclidine-like compounds is 
also found in the channel; the glycine (GLY) binding site is located on NR1 subunits; 
polyamine binding sites are located densely on, but not confined to, NR2B subunits 
(discussed in the following section); the ifenprodil binding site, which also appears to 
bind several structurally related compounds (e.g. eliprodil), is also found on NR2B. 
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 NMDArs are unique compared to other ionotropic receptors in that ion flux through 
the channel relies on three events. Firstly, GLY must bind NR1, co-activating the 
receptor. Secondly, GLU (or NMDA) must bind NR2. Finally, GLU must bind AMPArs 
or KArs, inducing partial depolarization of the membrane. This partial depolarization 
releases Mg2+ from the pore, allowing Ca2+ and Na+ flux through the channel. The 
requirement of both GLU binding and partial depolarization of the resting potential allow 
the NMDAr to act as a molecular “coincidence detector”, facilitating its roles in long-
term potentiation and synaptic plasticity. 
 
 Crystallization studies have demonstrated that NR1/NR2 dimers form within the 
receptor complex, providing allosteric modulation of gating activity. NR1 subunits are 
ubiquitous in brain, and expressed as at least eight splice variants (Nakanishi et al., 1992). 
Four NR2 transcripts have been identified (NR2A-D), and are implicated in the 
pharmacologic specificity of the receptor, such that various subunit combinations can 
differ widely in their pharmacology (Wafford et al., 1993; Monaghan et al., 1998; Cull-
Candy et al., 2001). NR2 subunits appear to determine the synaptic localization and 
function of the receptor, as NR2 C-terminal deletion disrupts receptor localization, 
activity, and plasticity (Chung et al., 2004). While receptor stoichiometries are clearly 
localization-dependent in brain, the degree to which ternary versus binary compositions 
are found is a matter of some debate. It has been suggested that NR1/NR2A/NR2B 
composition is the most abundant, with binary species present at much lower levels, 
however the opposite has also been suggested (Chazot & Stephenson, 1997; Blahos & 
Wenthold, 1996). Of particular interest to the current project is the NR2B subunit, for a 
variety of reasons; NR2B appear highly plastic, are concentrated in areas known to be 
particularly sensitive to ETOH and contain a major binding domain for polyamines. 
 
2.6.2 Polyamines 
 Polyamines are simple cation compounds, derived from the amino acid arginine. 
Arginine can be converted into ornithine, which is then further converted to putrescine 
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via ornithine decarboxylase (ODC) the rate limiting step in the synthesis of polyamines. 
Alternatively, arginine can be converted to agmatine and then further converted to 
putrescine, however this pathway appears to account for only a small portion of 
polyamine production. Putrescine is the precursor for two other major polyamines, 
spermine and spermidine, converted via spermidine synthase and spermine synthase, 
respectively (see Figure 1). These polyamines are ubiquitous in brain, and are involved in 
cell proliferation, differentiation, growth and apoptosis (Slotkin & Bartolome, 1986; 
Slotkin et al., 2000). 
Figure 1. Simplified Polyamine Biosynthesis  
 
 
 Polyamines bind to NMDArs at several sites (Williams et al., 1995; Kashiwagi et 
al., 1996; Zheng et al., 1999; Sharma and Reynolds, 1999), and spermine and spermidine 
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potentiate GLU-mediated responses by binding to the receptor and allosterically 
increasing GLU binding affinity (Williams, 1997a). Putrescine appears to act differently, 
exhibiting some antagonistic effects (Romano et al., 1992). Due to the diminished 
implication of putrescine in NMDAr activity, and its significantly lower concentration in 
brain (4-70 nM/g vs. 50-1400 nM/g for spermine/spermidine; Seiler and Schmidt-
Glenewinkel, 1975; Shimizu et al., 1964), for the purposes of this dissertation 
‘polyamines’ will refer primarily to spermine and spermidine. Polyamines exert this 
effect even in the presence of saturating concentrations of GLY (‘GLY-independent 
stimulation’; Benveniste & Mayer, 1993; Lerma, 1992; Rock & Macdonald, 1992), 
however a GLY dependent mechanism has also been noted, with polyamines increasing 
the affinity of GLY binding (GLY-dependent stimulation; Benveniste & Mayer, 1993; 
McGurk, Bennett & Zukin, 1990). Furthermore, voltage-dependent inhibition, possibly 
involving polyamine interaction within the channel has also been noted (for reviews see 
Dodd, 2000; Williams, 1997b). Subunit composition appears to strongly influence the 
aforementioned effects. For instance, GLY-dependent stimulation appears to occur 
regardless of composition (in NR2A/2A, 2B/2B and 2A/2B stoichiometries), while GLY-
independent stimulation is favored by a composition including NR2B subunits (for 
review see Williams, 1997). While polyamines are known to affect NR2A-containing 
receptors, it is the presence of NR2B which appears to confer polyamine sensitivity 
(Williams et al., 1994; Gallagher et al., 1997; Sharma and Reynolds, 1999).  
 
2.6.3 NMDArs and ETOH 
 Behavioral and molecular examinations strongly implicate the NMDAr in the acute 
actions of ETOH. Early in vitro studies have demonstrated ETOH’s inhibition of 
NMDAr-mediated transmission (Lovinger, et al., 1989; Hoffman et al., 1989). Since then, 
such observations have been confirmed and elaborated upon by examining slices in 
cortex (Wright, Peoples & Weight, 1996; Wirkner et al., 2000), amygdala (Calton, 
Wilson & Moore, 1998), NAcc (Maldve et al., 2002; Nie, Madamba & Siggins, 1994), 
dorsal striatum (Yin et al., 2007; Wang et al., 2007; Popp et al., 1998) and hippocampus 
(Wright, Peoples & Weight, 1996; Lovinger, White & Weight, 1990; Morrisett, 1991; 
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Kolb, Trettel & Levine, 2005). While the literature has focused on post-synaptic 
mechanisms of inhibition, more recent evidence suggests ETOH interactions with the 
receptor may also involve a presynaptic component (Hendricson et al., 2004; Zhu et al., 
2007). It remains unclear exactly how and where ETOH binds the receptor; it does not 
appear to block the channel (Reynolds & Rush, 1990), to compete with GLU binding 
(Abdollah & Brien, 1995), polyamine binding (Matsumoto et al, 1993), Mg2+ or Zn2+ 
binding (Morrisett et al., 1991; Chu et al., 1995). However, evidence for ETOH 
occupation of hydrophobic pockets (Peoples & Weight, 1992; Ren et al., 2003; Ronald et 
al., 2001) has been observed, which suggests ETOH functions allosterically to alter 
channel-gating properties and is consistent with observations of its wide-ranging 
pharmacology.  
 
 NMDArs appear involved in the discriminatory stimuli involved in ETOH 
exposure. NMDAr antagonists substitute for ETOH in two-choice discrimination 
(Bienkowski et al., 1996; Kotlinska and Liljequist, 1997; Grant, 1999; Holter et al., 
2000). While such discrimination studies clearly implicate the NMDAr as a primary 
target of ETOH, the recognition that GABA-A or 5-HT agonists can also substitute for 
ETOH in drug discrimination highlight both the complexity of its CNS action, and its 
lack of selectivity for any single transmitter system (Hodge & Cox, 1998; Grant, 1999; 
Hodge et al., 2001). It is known that the training dose of ETOH used in discrimination 
studies alters the degree to which NMDAr antagonists can act as substitutes, with higher 
concentrations involving a stronger NMDAr component (Colombo & Grant, 1992; Green 
& Grant, 1998). This is particularly interesting, suggesting that at higher doses 
(associated with AUDs), the NMDAr may become a more important target for ETOH, 
and thus perhaps a more important target for pharmacological intervention in treating 
alcoholism. 
 
 ETOH inhibition of NMDAr function appears to depend, at least in part, on subunit 
composition. Receptors containing NR2A and/or NR2B subunits appear to display much 
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greater sensitivity to alcohol than those including NR2C or NR2D (Kuner et al., 1993; 
Mirshahi & Woodward, 1995; Masood et al., 1994; for reviews see Allgaier, 2002; 
Sucher et al., 1996). However, whether NR2A or NR2B is the critical subunit for ETOH 
interactions remains a matter of some debate. Early studies suggested ETOH targeted 
NR2B-containing NMDArs (Lovinger, 1995; Fink & Gothert, 1996), however such 
claims were at least partially refuted with demonstrations in the cerebellum, where NR2C 
is abundantly expressed (Popp et al., 1999). Furthermore, examinations in hippocampus 
have produced divergent results, suggesting both NR2A (Suvarna et al., 2005) and 
NR2B-specific (Izumi et al., 2005) action. Such examinations are further complicated by 
the lack of NR2A-specific NMDAr antagonists, the suggestion that NR1 splice-variant 
expression affects sensitivity (Jin & Woodward, 2006) and noted differences in 
sensitivity depending on expression system (Smothers et al., 2001). A recent study 
utilized NR2A knockout mice to demonstrate equivalent ETOH inhibition of both 
knockout and wild types, suggesting the presence of NR2A is not a requirement for 
NMDAr inhibition (Kash et al., 2008), however, this demonstration was conducted in the 
ventral bed nucleus of the stria terminalis, and while supported by other examinations 
(Roberto et al., 2004; Izumi et al., 2005), these results may be unique to the regions 
studied. While NR2A-specific interactions are still being explored, the current literature 
suggests a substantial interaction with NR2B-containing NMDArs, which is further 
described and explored in the current project. 
 
 Exposure to ETOH is known to change NMDAr function and expression, 
particularly following chronic and/or binge-like exposure, and during withdrawal (WD) 
from ETOH. NMDAr upregulation appears to occur following chronic treatment (for 
reviews see Tabakoff & Hoffman, 1996; Kumari & Ticku, 2000). Ligand binding and 
autoradiography has demonstrated increases in receptor number following chronic 
exposure (Grant et al., 1990; Gulya et al., 1991; Snell et al., 1993), however examinations 
of subunit alterations reveal some inconsistencies. It seems that following chronic 
exposure, NR2B may be upregulated in cortex (Follesa & Ticku, 1995; Kalluri et al., 
1998) and hippocampus (Hardy et al., 1999; Follesa & Ticku, 1995; Kalluri et al., 1998), 
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however some examinations failed to detect this upregulation (Chandler et al., 1997). 
Importantly, while much of this literature utilizes rodents, ETOH-associated increases in 
NR2B have been noted in humans (Biermann et al., 2007; Biermann et al., 2009). 
 
 ETOH-related NR2A increases in hippocampus are found consistently (Kalluri et 
al., 1998; Follesa & Ticku, 1995; Snell et al., 1996). However, cortical increases were 
detected by some groups (Follesa & Ticku, 1995; Chandler, 1999), but not others (Snell 
et al., 1996; Hu et al., 1996; Follesa & Ticku, 1996a; 1996b; Chandler et al., 1997). NR1 
examinations have been similarly inconsistent, with upregulation detected in 
hippocampus by some (Snell et al., 1996; Trevisan et al, 1994; Kalluri et al., 1998), but 
not others (Follesa & Ticku, 1995), and in cortex by some (e.g., Chandler et al., 1999; 
Kalluri et al., 1998) but not others (e.g., Snell et al., 1996; Hu et al., 1996). While the 
variables contributing to such inconsistent results have not yet been fully elucidated, the 
basic finding that ETOH increases subunit expression, resulting in enhanced NMDAr 
agonist sensitivity, is well supported. Furthermore, polyamines appear to play a complex 
role in mediating effects of ETOH on the NMDAr (Davidson and Wilce, 1998; for review 
see Littleton et al., 2001), and are increased following chronic exposure. The 
implications of both subunit and polyamine increases are thought to be far-reaching for 
dependence, relapse, and ETOH-associated neurotoxicity, areas which are primary foci 
of the current work, and which are discussed at length in their respective sections, below. 
 
  
Copyright © Ben Lewis 2011 
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Chapter 3. ETOH-Associated Brain Damage 
 AUDs are associated with cognitive deficits and neurodegeneration, although even 
moderate drinking has been associated with reduced cognitive function (Evert & Oscar-
Berman, 1995). A subset of alcoholics display deficits in intellectual functioning, with 
the most prevalent impairments including visuo-spatial ability and higher cognitive 
function (Oscar-Berman et al., 1997). Imaging studies have revealed reductions in brain 
size and density (Pfefferbaum, et al., 1988; Pfefferbaum et al., 1992), most noticeable in 
cortex and cerebellum, regions in which brain activity also appears altered in heavy 
drinkers (Eberling & Jagust, 1995). Fortunately, many such deficits in structure and 
function appear at least partially reversible during abstinence (e.g., Sullivan et al., 2000; 
Sullivan, Rosenbloom & Pfefferbaum, 2000). Of particular relevance to the current work, 
cognitive impairments appear most severe during and immediately following acute WD 
(Allen, Goldstein & Seaton, 1997). 
 
3.1 Mechanisms of Damage 
 The proposed mechanisms underlying deficits originating from either adulthood or 
fetal exposure are numerous: oxidative stress, non-oxidative metabolites (e.g., fatty acid 
ethyl esters), malnutrition, HPA-axis dysfunction, intracellular microtubule disruption 
and excitotoxic cellular damage have all been implicated (Butterworth, 1995). While 
multiple mechanisms undoubtedly contribute to ETOH-induced damage, the current work 
focuses on GLU and disrupted GLUr function, which appear to play primary roles. While 
ubiquitous, and crucially important to homeostatic function, GLU can also be toxic; it is 
implicated in the pathogenesis of a wide variety of disorders, including ischemia 
(Hammerman & Kaplan, 1998), amyotrophic lateral sclerosis (for review see Bogaert et 
al., 2010), AIDS and/or HIV-associated dementia (Prendergast et al., 2002; Self et al., 
2004), neuropathic pain (for review see Brown & Krupp, 2006), Parkinson’s disease 
(Bonuccelli and Del Dotto, 2006), epilepsy (Tzschentke, 2002) and Huntington’s disease 
(Fan et al., 2007). GLU over-activation of NMDArs, leading to excessive Ca2+ entry, can 
induce several intracellular cascades which lead to both necrotic and apoptotic cell death. 
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This pathological excitation of the receptor is termed ‘excitotoxicity’ and appears to 
occur, at least in part, due to increases in NMDAr expression and sensitivity following 
chronic ETOH exposure (e.g., Hoffman et al., 1995; for review see Lovinger., 1993).  A 
major underlying hypothesis of the current project is that ETOH-associated cell death 
and neurodegeneration involves this hyper-excitable state, resulting in excitotoxic injury 
during withdrawal.  
 
 While the toxicity of GLU has been recognized for some time (Lucas & Newhouse, 
1957), this was followed by the identification of Ca2+ increases as a major contributor 
(Choi et al., 1985; Choi et al., 1987). Increases in intracellular Ca2+ may be achieved via 
multiple mechanisms, however, NMDAr-mediated Ca2+ entry has been critically 
implicated; higher concentrations of Ca2+ from alternate sources have been shown to be 
less toxic than lower concentrations whose source was NMDAr-mediated (Tymianski et 
al., 1993; Sattler, Charlton & Hafner, 1998). One proposed mechanism for the NMDAr-
specificity of excitotoxicity involves its intracellular coupling to neuronal nitric oxide 
synthase (nNOS; Sattler, Xiong & Lu, 1999); increased NO is a hallmark of excitotoxic 
events and major contributor to damage. NOS inhibitors are known to prevent cell death 
in vitro (Dawson et al., 1991), and resistance to NMDAr-mediated excitotoxicity is 
conferred by nNOS knockout (Dawson, Kizushi & Huang, 1996). The structural link 
between NMDAr and nNOS appears to involve a postsynaptic density protein associated 
with the C-terminus of the NR2B subunit and N-terminus of nNOS, creating a 
“microenvironment” wherein Ca2+ entering the cell via NR2B-containing NMDArs 
preferentially activate nNOS via calmodulin (Sattler, Xiong & Lu, 1999). NO appears to 
directly interact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to initiate 
apoptotic cascades (Hara et al., 2005), as well as the free radical superoxide, forming 
toxic peroxynitrite. Free radicals are highly reactive molecules formed during 
mitochondrial reactions with oxygen during energy production. Free radicals and 
peroxides are collectively referred to as reactive oxygen species (ROS) and when 
overproduced under pathological conditions, damage several intracellular structures 
including proteins, lipid membranes (Sun et al., 1997) and nucleic acids (Navasumrit et 
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al., 2000). “Oxidative stress” generally refers to both increases in ROS-associated 
intracellular damage (Reinke et al., 1987; Henderson et al., 1995; Davis et al., 1990), and 
reductions in the cell’s ability to compensate (Bailey et al., 2001). Excitotoxicity and 
oxidative stress are frequently dissociated in the literature as differential pathways of cell 
death, however the role of NO in excitotoxicity illustrates the interconnected nature of 
these pathways. ROS production following excitotoxicity is well-established (Dugan, 
Sensi & Canzoniero, 1995; Reynolds & Hastings, 1995) and appears dose-dependent 
with increased NMDAr activation (Lafon-Cazal et al., 1993). In sum, the literature 
suggests a model wherein excessive intracellular Ca2+ accumulation via NMDArs 
pathologically increases NO production and results in mitochondrial failure. ROS 
produced by such failure interact with NO to form peroxynitrite, directly damaging DNA 
and leading to the release of apoptosis-inducing factors from mitochondria, resulting in 
cell death (for review see Lau & Tymianski, 2010).  
 
3.2 Excitotoxicity & Polyamines  
 Polyamines may play a critical role in ETOH-associated excitotoxicity; increased 
polyamine expression has been reported in hippocampus, striatum, cortex, and 
cerebellum during periods of ETOH WD (Davidson & Wilce, 1998; Gibson et al., 2003). 
Increases in ODC expression (indexing increases in polyamine concentration) are noted 
in these areas following chronic ETOH exposure (Koenig et al., 1990; Shibley et al., 
1995; Davidson & Wilce, 1998). Additionally, polyamine activity seems to correlate 
positively with behaviors indexing the severity of WD-associated damage, including 
WD-induced tremor and seizure in dependent animals (Davidson & Wilce, 1998). 
Additionally, reductions in ODC activity correlate with reductions in severity of WD 
symptoms (Davidson & Wilce, 1998). In vitro examinations of WD-induced excitotoxic 
damage suggest that exogenous application of polyamines exacerbates damage (Butler et 
al., 2010; Mayer et al., 2002a), while polyamine antagonism (Gibson et al., 2003) 
attenuates damage. Furthermore, inhibition of polyamine synthesis via difluoromethyl 
ornithine, an ODC inhibitor, inhibits WD-induced seizure, improves WD-associated 
outcomes in vivo (Davidson & Wilce, 1998), and attenuates cell death in vitro (Gibson et 
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al., 2003). Taken together, this evidence suggests that the withdrawal state can be 
characterized by increases in polyamine-sensitive (NR2B-containing) NMDArs as well 
as increases in polyamine synthesis and accumulation. This suggests that polyamine 
modulation during WD may provide a useful substrate for pharmacotherapeutic 
intervention. Further evidence for this hypothesis is garnered from examinations of 
compounds that inhibit polyamine-sensitive NMDArs (reviewed below in section 5). 
 
  
Copyright © Ben Lewis 
2011 
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Chapter 4. ETOH Dependence 
 The aforementioned evidence implicates the GLU system in ETOH-associated 
neurotoxicity, however the selection of this system as a pharmacological target in the 
current project is also due to its contribution to ETOH dependence and withdrawal. While 
numerous neurotransmitter systems are involved, GLUergic intervention seems uniquely 
capable of reducing relapse risk through multiple mechanisms, including positive and 
negative reinforcement, as well as alterations in cue conditioning and salience. 
 
4.1 Acute & Protracted Withdrawal 
 Cessation of chronic ETOH consumption is associated with the alcohol withdrawal 
syndrome, characterized by autonomic hyperactivity, increased tremor, nausea/vomiting, 
anxiety, hallucination, psychomotor agitation and seizure (APA, 2000). Recent estimates 
suggest up to 2 million Americans experience symptoms of alcohol withdrawal per year 
(Bayard et al., 2004). Although acute withdrawal is potentially life-threatening, 
detoxification has become a routine medical procedure which rarely results in mortality 
(for review see Romach & Sellers, 1991). Current detoxification practices involve 
GABAergic manipulation via benzodiazepines, and are extremely effective at controlling 
withdrawal symptoms and morbidity, however there is no evidence for reductions in 
neurotoxicity or relapse risk following treatment. The current project focuses on 
developing compounds with the capability of reducing both toxicity and relapse. 
 Withdrawal can be characterized by increased glutamatergic activity and increased 
stress/anxiety. While the most severe withdrawal symptoms generally dissipate within 1-
2 weeks, symptomology and underlying altered brain function can persist for months, and 
possibly much longer. It is hypothesized that such altered glutamatergic function and 
negative affect during both acute and protracted withdrawal contribute to increased 
relapse risk.  
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4.1.1 Glutamatergic Hyperactivity 
 Extracellular concentrations of GLU appear increased following withdrawal, and 
are highly correlated with withdrawal symptomology (Gonzales et al., 1996; Rossetti & 
Carboni, 1995). The hyperexcitability during withdrawal appears mediated by NMDArs, 
whose upregulation following chronic exposure is well-established; a similar syndrome 
of hyperexcitability is noted following withdrawal from chronic NMDAr antagonism 
(Ripley & Little, 1995). Furthermore, GLU inhibition during withdrawal reduces 
symptom severity (Grant, 1990; Liljequist, 1991; Morrisett et al., 1990; Rossetti & 
Carboni, 1995) while agonism worsens it (Danysz et al., 1992; Davidson et al., 1995; 
Morrisett et al., 1990; Sanna et al., 1993). As noted above, elevations in polyamines 
appear to contribute to this hyperactivity, and polyamine inhibition is also capable of 
reducing WD symptoms (Davidson & Wilce, 1998). 
 
 GLU hyperactivity also appears to contribute to ETOH dependence and relapse 
(Tsai & Coyle, 1998; Pulvirenti & Diana, 2001; Siggins et al., 2003; Heinz et al., 2003; 
Krystal et al, 2003). Although the exact mechanisms are still being investigated, GLU-
mediated increases in cue salience and incentive motivation for ETOH during withdrawal 
are implicated. Additionally, GLU hyperactivity may exacerbate negative affect during 
withdrawal, indirectly increasing cue salience and ETOH reinforcement further. Though 
discussed in greater detail below, a simple schematic of these relationships is presented in 
Figure 2. 
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Figure 2. Contributions of ETOH Withdrawal to Reinforcement and Cue Salience 
 
 
 
4.1.2 Stress, Anxiety & Negative Affect 
Withdrawal from chronic ETOH increases anxiety (Rassnick et al., 1993; Valdez 
et al., 2002).  Stress & anxiety during withdrawal appear closely related to resumption of 
drinking in humans (Hershon, 1977). Stress responses are controlled by the 
hypothalamic-pituitary-adrenal (HPA) axis; basic functioning of this system involves 
CNS stimulation of corticotropin-releasing hormone from hypothalamus, inducing 
pituitary secretion of adrenocorticotropin, resulting in adrenal glucocorticoid (GC; 
cortisol, in humans) production. Alcohol intoxication and withdrawal are known to 
increase GCs (Adinoff et al., 1991; Keedwell et al., 2001; Mendelson et al., 1971), with a 
number of implications. Hippocampal GCrs, via negative feedback, are responsible for 
regulating HPA-axis activity and recovery. Chronically elevated GC levels and chronic 
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ETOH binge/WD cycles are known to induce hippocampal damage, disrupting negative 
feedback control and dysregulating the HPA system (for review see Adinoff et al., 1998). 
 
Both GLU hyperactivity and disrupted HPA-axis activity are thought to contribute 
to relapse behaviors by altering ETOH reinforcement and ETOH-associated cue salience, 
as indicated in Figure 2. However, these systems also appear to interact with one another 
dynamically during withdrawal. GC exposure upregulates polyamine-sensitive NR2B 
subunit expression (Lu et al., 2003), as well as increasing the production of polyamines. 
(Weiland, Orchinik & Tanapat, 1997). Finally, GC elevations upregulate excitatory 
amino acid activity, increasing Ca2+ flux via NMDAr (for review see, Reagan & 
McEwen, 1997; Armanini et al., 1990). However, inhibition of GLUrs is anxiolytic 
(Dunn et al., 1989; Faiman et al., 1994), protects from GC-associated hippocampal 
neurotoxicity (Mulholland et al., 2005), and reduces WD-associated behaviors indexing 
stress (Cagetti et al., 2004).  
 
Taken together, these interactions suggest that GLU inhibition during withdrawal 
may serve to balance GLU activity both directly, as well as indirectly, by preventing 
increased GC activity via neuroprotection to critical (hippocampal) stress-regulation 
circuitry. Thus, reductions in GLU activity are likely to reduce negative affect and HPA-
axis dysregulation, both critical contributors to relapse. 
 
4.2 Relapse & ETOH Reinforcement 
Following cessation of chronic drinking, the majority of dependent individuals 
will experience a relapse, despite efforts to maintain sobriety (Hayashida et al., 1989; 
Prochaska, DiClemente, & Norcross 1992). Preventing relapse is a (if not the) major 
therapeutic challenge in treating ETOH dependence. Contemporary theories of relapse 
hold that following chronic consumption and cessation, drug-associated alterations in 
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neurochemistry contribute to a state in which the reinforcing value of the drug is 
increased during sobriety.  
 
Positive reinforcement is indicated when a stimulus (alcohol) increases the 
probability of a particular response (consumption or ETOH-seeking behavior). Negative 
reinforcement is indicated when the probability of the response is increased when it 
allows for escape or alleviation from an aversive stimulus (e.g., anxiety). It is now 
generally agreed that the pathogenesis of alcoholism can be described as a transition from 
motivation to consume ETOH based on its positive reinforcement, to compulsive use 
associated with its alleviation of the negative affective state created during WD. This 
conceptualization of addiction, wherein use becomes driven by homeostatic maintanance 
has been described as ‘allostasis’ originated with Himmelsbach (1943) following his 
work in opiate dependence, and was not described as ‘allostasis’ until much later 
(Sterling and Eyer, 1988). Allostasis describes the dynamic adaptation of multiple 
systems to achieve (or restore) homeostatic function, making it a particularly apt 
description of the varied physiological adaptations to drugs of abuse noted in dependence 
& addiction. Allostasis has become a primary, driving conceptual model in the field (e.g., 
Koob & Le Moal, 2001; Koob & Volkow, 2010). 
 
 While progression from positive to negative reinforcement as a basic concept has 
been popularized, it potentially ignores a subset of individuals with high stress/anxiety 
prior to initiation of use, whose primary initial motivation to consume may involve 
ETOH’s anxiolytic properties. Regardless of initial motivation, following the cessation of 
chronic consumption, ETOH-exacerbated negative affect is thought to persist for months 
or longer, is referred to as “protracted withdrawal” and is characterized by stress, anxiety, 
depression and hyperalgesia (Koob, 2003). Thus, heightened negative reinforcement for 
consumption of ETOH appears to remain persistent despite the absence of acute 
withdrawal symptoms. However, sensitization to the positive reinforcing value of ETOH 
may also contribute to its enhanced reinforcing value during withdrawal. 
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Conceptualizations of conditioning and relapse based on positive vs. negative 
reinforcement can be referred to as ‘incentive salience’ vs. ‘opponent-process’ models, 
respectively. Incentive salience models suggest that drug cues will produce conditioned 
drug-like responses (euphoria), which enhance the incentive motivation to consume the 
drug. Opponent-process models suggest that with prolonged drug use, physiological 
‘drug-opposite’ responses to conditioned cues develop to maintain homeostasis. In a 
drug-free state, exposure to such cues produces a dysphoric state in which the negative 
reinforcing value of the drug is increased. Importantly, both of these views hold that 
relapse involves a state wherein the increased reinforcing value of drugs is “triggered” by 
environmental cues. 
 
It is clear that ETOH has both positive (euphoric, stimulating) and negative 
(anxiolytic) reinforcing effects. DA efflux in NAcc has received the most attention as a 
biological requirement for positive reinforcement, however as noted above, mesolimbic 
dopamine is modulated by input from a number of transmitter systems (including GLU). 
Pharmacological interventions which reduce DA efflux or blunt its effects are noted for 
their ability to disrupt ethanol consumption in humans and animals (discussed in greater 
depth below). Glutamate tone, NAcc DA levels, ETOH consumption and ETOH’s 
positive reinforcing value all appear closely related; NAcc DA levels increase in 
anticipation of ETOH consumption, suggesting an important role for cue-associated 
increases in positive reinforcement during relapse (Katner, Kerr & Weiss, 1996; 
Melendez et al., 2002). Furthermore, manipulation of NAcc GLU via microinjection of 
GLUr inhibitors (including NMDAr antagonists) reduces drinking (Rassnick, 1992; 
Besheer et al., 2010), emphasizing the GLUergic component of ETOH’s reinforcing 
effects. 
 
 In one particularly interesting study, Spanagel and colleagues (2005) genetically 
altered astrocytic GLU transporter expression to create mutants with persistently high 
synaptic GLU activity (as is known to occur in ETOH withdrawal). These mutants 
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demonstrated increased ETOH intake and increased operant responding for ETOH. 
Further demonstrating GLUergic control of the behavior, Spanagel’s group 
pharmacologically inhibited the GLU hyperactivity and observed normalized 
consumption. However, while this work appears to implicate GLUergic mechanisms in 
positive reinforcement (since the animals received no aversive stimuli or previous ETOH 
exposure) an alternative interpretation suggests that such persistently high synaptic GLU 
activity may produce a negative affective state, potentially driving consumption. This 
interpretation is consistent with observations that the negative reinforcing properties of 
ETOH are also mediated via GLUrs.  
 
That ETOH reinforcement can also be driven by negative components is 
emphasized by the finding that ablation of the mesolimbic DA system fails to extinguish 
ETOH consumption (Rassnick et al., 1993). A major underlying hypothesis of the current 
project is that inhibition of GLUergic activity during acute and protracted withdrawal can 
mitigate negative affect, thereby reducing ETOH’s negative reinforcing value. 
Supporting evidence includes that GLU inhibition can reverse or attenuate dysregulation 
in HPA-axis function (described above) and that numerous compounds with GLUergic 
action which are shown to reduce consumption and relapse behavior (clinically and 
preclinically) possess anxiolytic action. Finally, amygdalar nuclei which regulate 
negative affect, particularly anxiety and fear responses, are implicated as key modulators 
of ETOH reinforcement and appear sensitive to GLU imbalance. The basolateral 
amygdala is rich in GLU receptors (Farb et al., 1995; for review see Davis et al, 1994;) as 
is one of its major efferents, the central nucleus (CeA; Nose et al., 1991; Davis et al., 
1994). GLU levels in these areas are persistently higher in animals chronically exposed to 
ETOH (Roberto et al., 2004), contributing to the anxiogenic properties of WD. Similarly, 
reductions in GLUergic transmission in these areas, whether due to ETOH or NMDAr-
specific antagonism, produce anxiolytic effects (Miserendino et al., 1990; Kim et al., 
1993). Of particular importance to the current project, amygdalar neuroadaptations to 
chronic ETOH appear mediated by NR2B-containing NMDArs; CeA NR2B upregulation 
is persistent (> 4 weeks; Obara et al., 2009) following chronic exposure and the 
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heightened sensitivity of CeA NMDArs to ETOH observed following such exposure is 
attenuated via NR2B-specific antagonism (Roberto et al., 2004). 
 
Taken together, the aforementioned evidence suggests that (i) ETOH consumption 
is under the control of both positive and negative components of reinforcement; (ii) that 
both positive and negative components are mediated at least in part by GLU; (iii) and that 
GLU inhibition, specifically NMDAr inhibition, appears capable of reducing both types 
of reinforcement.  
 
4.2.1 Conditioned Cues 
Changes in the reinforcing value of ETOH during withdrawal increase relapse 
risk, serving to prime the system for relapse, however cues or “triggers” which reinstate 
the conditioned behavior of alcohol seeking are also critically involved. In traditional 
conditioning models, environmental cues (including ETOH itself, referred to as ‘priming’ 
cues) become associated with alcohol use, after which they function as classically 
conditioned stimuli, evoking conditioned physiological responses. These appear to induce 
alcohol-related effects that can include feelings of euphoria (drug-similar responses) 
and/or feelings of withdrawal (drug-opposite responses referred to as “conditioned 
pseudo-withdrawal” (Solomon, 1980; O’Brien et al., 1998), both of which may result in 
‘craving’ or the desire to experience alcohol’s effects. As mentioned previously, 
divergent models of relapse/reinforcement conceptualize craving as being driven by 
either euphoric or dysphoric feelings, however contributions are likely to vary on an 
individual basis and it is suggested that even within individuals craving and relapse may 
be precipitated by a variety of environments and/or internal states (Connors et al., 1996). 
Regardless of reinforcement mechanism, extinction of these conditioned cues appears to 
improve relapse measures (Glautier & Drummond, 1994).  
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Protracted relapse constitutes a period of heightened stress and anxiety, during 
which acute stressors are known to trigger conditioned relapse (Annis, 1998; Sinha et al., 
2000; for review see Sinha, 2001). Interestingly, acute stress also appears to have a 
permissive function, enhancing the salience of other conditioned ETOH cues (Field & 
Powell, 1997). This may be a bi-directional relationship, since (as opponent-process 
theory would predict), exposure to alcohol cues via guided imagery in abstinent 
alcoholics increases negative affect (Cooney et al. 1991, Sinha et al., 2000). However, 
stress-induced relapse appears to operate via dissociable neural mechanisms from cue-
induced relapse; Liu & Weiss (2002) demonstrated that opioid antagonism could 
attenuate cue-induced, but not stress-induced reinstatement of drinking, while a CRF 
antagonist suppressed stress-induced, but not cue-induced consumption. When animals 
were simultaneously exposed to both conditioned cues (a situation with greater face 
validity to human behavior), both the CRF and opioid antagonist were only capable of 
partial mediation. Their experiment highlights the complexity of relapse/reinstatement 
behavior, and suggests that an ideal pharmacological intervention would be capable of 
attenuating both stress and cue-induced reinstatement. 
 
 As suggested in Figure 2, in addition to impacting reinforcement, the GLUergic 
system is critically involved in the conditioning and expression of ETOH-associated cues. 
ETOH cue-induced reinstatement of self-administration has been demonstrated and 
attenuated in dependent animals via GLU inhibition (e.g., Backstrom & Hyytia, 2004). 
Additionally, GLU inhibition reduces responding for ETOH-associated cues in 
conditioned place preference studies (McGeehan & Olive, 2003; Brown, Lee & Sorg, 
2008; Gremel & Cunningham, 2009). More recent examinations have suggested specific 
GLUr subpopulations, particularly NMDArs containing polyamine-sensitive subunits, 
may be critical for drug-associated conditioning. In general, polyamines are known to 
enhance learning and memory processes (Rubin et al., 2000; 2001; Mikolajczak et al., 
2002), including cue-associated conditioning (Rubin et al., 2004). However, inhibiting 
NMDArs via polyamine modulation reduces drug-associated responding while leaving 
responding for natural reinforcers intact (Ma et al., 2006). Although not yet examined 
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directly, these findings suggest that known increases in polyamine expression and 
sensitivity during ETOH withdrawal may enhance conditioned responding to alcohol-
associated cues. 
 
 Taken together, evidence presented in the preceding sections suggests that chronic 
ETOH exposure is associated with neurotoxicity and pathological alterations in both 
GLU and HPA-axis function. These changes are associated with increases in the 
reinforcing value of ETOH, and increased sensitivity to ETOH-conditioned cues, both of 
which increase relapse risk. The complexity and range of the involved mechanisms 
suggests numerous substrates for pharmacological intervention (discussed below), 
however based on evidence discussed above, inhibition of polyamine-sensitive NMDArs 
may provide a unique opportunity to simultaneously reduce excitotoxicity, GLU 
hyperactivity and negative affect during WD, the downstream effects of which include 
reductions in reinforcing value (positive and negative) of ETOH and sensitivity to ETOH-
conditioned cues. Additional evidence for this hypothesis is garnered from examinations 
of a number of pharmacological interventions, presented below. 
  
Copyright © Ben Lewis 2011 
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Chapter 5. Pharmacotherapy 
 While the current work is focused on mediation of ETOH-associated alterations in 
physiology and behavior via NMDAr-targeted pharmacotherapy, several FDA-approved 
pharmacological interventions already exist, as do a number of potentially useful 
strategies which do not target the NMDAr. Disulfiram and naltrexone are discussed here, 
while the third FDA-approved compound (acamprosate) will be discussed with other 
GLUergic compounds, below. 
 
5.1 Disulfiram 
 Disulfiram (Antabuse) has been FDA-approved since 1951. Disulfiram inhibits the 
enzyme acetaldehyde dehydrogenase (ADH), stimulating a number of negative symptoms 
normally associated with WD (“hangover”) from ETOH (e.g., nausea, vomiting). It is 
unique in that it acts indirectly, providing a punishing stimulus when ETOH is consumed. 
Early studies reported high efficacy, while later results have been more mixed. 
Regardless, the most recent data indicate that with supervised use, which greatly 
improves patient compliance, disulfiram has clinical utility (for review see Fuller & 
Gordis, 2004).  
 
5.2 Naltrexone 
 Naltrexone (ReVia, Depade) was FDA-approved in 1995; its extended release 
formula (Vivitrol) was approved in 2006. Both naltrexone and its active metabolite, 6-β-
naltrexol, competitively antagonize opioid receptors, particularly μ receptors, leading to 
reductions in NAcc DA levels (Benjamin & Grant, 1993; Gonzales & Weiss, 1998; 
Middaugh et al., 2003). Such reductions are associated with reduced ETOH consumption, 
as has been shown in several clinical studies (Latt et al., 2002; Krystal et al., 2001), as 
well as demonstrated by the multi-center COMBINE study, which suggested efficacy 
when administered apart from adjunct psychotherapeutic intervention (Anton et al., 
2006). Such recognized efficacy has been demonstrated by a number of meta-analyses 
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(e.g., Kranzler & Van Kirk, 2001; Streeton & Whelan, 2001; for review see Anton, 2008; 
Bouza et al., 2004). Naltrexone is recognized to reduce craving associated with 
environmental cues, reducing conditioned anticipation of ETOH (Monti et al., 1999; 
Middaugh & Bandy, 2000), however such reductions are likely to result from blunting of 
incentive motivation associated with ETOH, rather than weakened cue conditioning. 
 
5.3 Current Promising Strategies 
 While not yet FDA-approved, a number of additional pharmacotherapeutic agents 
are currently being investigated for abstinence maintenance and relapse prevention (for 
review see Johnson et al, 2008). Several do not employ GLUergic manipulation; for 
instance, specific serotonin reuptake inhibitors (SSRIs) have been employed in a number 
of preclinical models, with mixed results. It appears that SSRI treatment is capable of 
reducing ETOH consumption and operant responding for ETOH (Haraguchi, Samson & 
Tolliver, 1990; Murphy et al., 1988). However, evidence suggests that such attenuations 
may be non-specific, resulting in suppressions of food and fluid intake (Simpson et al., 
1981; for review see Gill & Amit, 1989). Furthermore, it is suggested that while SSRIs 
are capable of initial reductions in consummatory behavior, rebound to baseline levels are 
noted (Gulley et al., 1995). Clinical investigations appear to produce short-term decreases 
in consumption, but many have limited longevity: there is evidence that initial decreases 
do not persist after the first month of treatment (Gorelick & Paredes 1992; for review see 
Kenna, 2010). However, it is recognized that SSRIs may have unique utility among 
ETOH-dependent populations with comorbid depressive symptoms (Pettinati et al., 
2010). 
 
 While restoring homeostatic GLU tone during and after WD is a focus of the 
current work, agonism of GABAr to restore GLU/GABA balance has also been explored. 
For instance, the GABA-B agonist, baclofen, decreases consumption (Colombo et al., 
2000; Colombo et al., 2002), operant responding for ETOH (Colombo et al., 2003a) and 
reduces relapse-behavior (Colombo et al., 2003b), preclinically. In humans, baclofen 
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shows efficacy in reducing cravings and improving abstinence (Addolorato et al., 2000; 
for review see Leggio et al., 2010), effects which may be related to reductions in WD-
associated anxiety and negative affect. While promising, clinical examinations of 
baclofen are limited, and it’s noted sedative properties may interact negatively with acute 
ETOH intoxication. 
 
 Given the aforementioned involvement of the HPA axis in WD, protracted 
withdrawal, and the negative reinforcing effects of ETOH, it is not surprising that direct 
manipulation of this system has been investigated as a pharmacotherapeutic strategy. 
Antagonists of corticotropin-releasing factor (CRF) have received significant attention; it 
is known that ETOH WD increases CRF levels (Merlo Pich et al., 1995; Olive et al., 
2002), and that CRF antagonists attenuate stress and anxiety responses (Britton et al., 
1986). Thus, CRF antagonists appear capable of attenuating ETOH WD-induced stress 
responses (Baldwin et al., 1991). Interestingly, CRF antagonists, while anxiolytic in 
nature, appear capable of reducing ETOH consumption in models that other anxiolytics 
(e.g., diazepam) do not, perhaps suggesting the specific modulation of HPA-axis function 
is necessary, as opposed to general reduction in anxiety/negative affect (Lodge & 
Lawrence, 2003). 
 
 Additional investigations include cannabinoid receptor antagonists, DAr 
antagonists (e.g., aripiprazole), DAr agonists (e.g., bromocriptine), 5-HT antagonists (e.g. 
ritanserin), 5-HT agonists (e.g., buspirone), nAChR antagonists (e.g., varenicline), and 
others. While all have demonstrated some clinical potential, many have significant side 
effects or show efficacy only in limited clinical populations. Furthermore, and perhaps 
most importantly for our strategic approach, neither of the aforementioned FDA-
approved compounds, nor these experimental approaches, are noted for significant 
neuroprotection. 
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5.4 Acamprosate 
 The current project focuses on GLUergic manipulation, a key characteristic of 
which may be the ability to alter relapse trajectories while offering neuroprotection 
during acute and protracted withdrawal (an ability which may synergize with anti-relapse 
mechanisms). However, this is not a novel area of investigation. A number of GLUergic 
manipulations have been explored, both clinically and preclinically, and the third FDA-
approved medication, acamprosate, is thought exert its effects primarily via GLUergic 
action. 
 
 Acamprosate (Campral) is structurally related to a number of amino acids thought 
be to critically important to ETOH’s CNS actions, including GLU, GABA and GLY 
(Spanagel & Zieglgansberger, 1997). These similarities contribute to its varied 
pharmacology (for reviews see Littleton, 1995; Littleton et al., 2001; De Witte et al., 
2005; Mann et al., 2008); it is recognized as an anti-oxidant (Dahchour et al., 2005), 
GABA-A agonist (Pierrefiche et al., 2004), NMDAr antagonist (Zeise et al., 1993), 
polyamine modulator (Al Qatari et al., 1998; Naassila et al., 1998; Popp & Lovinger, 
2000), and Group I mGLUr antagonist (Harris et al., 2002). Despite FDA approval, the 
mechanism of action contributing to its anti-relapse efficacy is equivocal. However, it 
appears capable of normalizing elevated extracellular GLU following repeated binge-WD 
cycles (Dahchour & De Witte, 2003; Ulrichsen et al., 1998), and it is generally agreed 
that this action contributes to reductions in the negative reinforcement of ETOH during 
WD and protracted withdrawal. In animal models, acamprosate inhibits WD-associated 
behaviors (Spanagel & Ziegelgansberger, 1997), reduces relapse behavior (Spanagel et 
al., 1996), suppresses conditioned pseudo-withdrawal behavior (Cole, Littleton & Little, 
1999) and attenuates cue-induced ETOH-seeking behaviors (Bachteler et al., 2005). 
Clinically, acamprosate appears effective at reducing a number of behavioral endpoints 
associated with relapse-risk and abstinence maintenance (Mason et al., 2006; Feeney et 
al., 2006). 
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 Additionally, acamprosate appears to confer neuroprotection, reducing toxicity and 
Ca2+ entry in neocortical cultures (Al Qatari et al., 2001). In hippocampal cultures, which 
are used in the current project, acamprosate attenuates WD-associated Ca2+ entry and 
neurotoxicity (Mayer et al., 2002a;b), however acamprosate appears to have a unique 
neuroprotective profile, thought to include mGLUr manipulation, as it is noted to inhibit 
ETOH WD-associated toxicity but not NMDA-associated toxicity (Harris et al., 2003). 
 
The varied GABAergic and GLUergic interactions of acamprosate are similar in 
nature to topiramate (Topamax). In animal models, topiramate reduces stress-induced 
relapse behaviors (Farook et al., 2009) and ETOH cue-conditioned behaviors during WD 
(Farook et al., 2007). Clinically, the drug appears efficacious (Johnson et al., 2003;2007), 
and may share acamprosate’s neuroprotective potential (Rustembegovic et al., 2002). 
 
5.5 Memantine 
 A number of GLUergic approaches have utilized NMDAr-specific antagonists. 
Classic channel-blockers are noted for their lack of clinical potential, however, low-
affinity, non-competitive antagonists appear to induce rapidly dissociating channel 
blockade and may have anti-relapse efficacy. One such compound in particular, 
memantine, has received attention. Due to its rapid dissociating kinetics, memantine is 
thought to interfere less with homeostatic NMDAr transmission, compared to classic 
channel blockade (Chen & Lipton, 1997; Bleich et al., 2003; Johnson & Kotermanski, 
2006; Lipton, 2006; for review see Kohr, 2007). It has shown anti-relapse potential 
(Krupitsky et al., 2007a) in humans, and appears to reduce WD symptoms (Krupitsky et 
al., 2007b). Memantine is also recognized for its neuroprotective potential in models of 
excitotoxicity (Lipton, 2007) including ETOH WD (Stepanyan et al., 2008). One 
criticism of an NMDAr-blockade strategy involves the potential disruption of learning & 
memory; MK-801 disrupts responding for natural rewards (Lee & Everitt, 2008; Bevins 
& Bardo, 1999), as does memantine (Popik et al., 2003). However, as noted previously, 
NR2B-specific antagonism may provide a solution, disrupting drug-associated cues while 
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leaving cues for natural reinforcers unperturbed (Ma et al., 2006). 
 
5.6 Ifenprodil & Eliprodil 
Due to the recognized contribution of the NR2B in ETOH-associated WD, cue-
conditioning and neurotoxicity, investigation of compounds capable of targeting NR2B-
containing subpopulations has been substantial. One such compound is ifenprodil, which 
is characterized as a non-competitive allosteric inhibitor of the spermine and Mg2+ 
binding sites, whose action exhibits use-dependence, such that bound GLU increases the 
receptor’s affinity for ifenprodil (Kew et al., 1998). A secondary mechanism of 
inhibition, shared by ifenprodil and its analogue CP-101,606 (described below), involves 
proton inhibition. NMDArs are inhibited by protons with an IC50 value that corresponds 
to pH 7.3 (e.g., Giffard et al., 1990; Tang et al., 1990; Traynelis & cull-Dandy, 1990). 
While this mechanism is largely understudied, a major function of such proton sensitivty 
appears related to its neuroprotective capacity during acidification of the extracellular 
space, noted during seizures and ischemia, during which pH can fall by up to 1 pH unit 
(e.g., Chesler & Kaila, 1992). Under conditions of excessive extracellular GLU, such 
decreases in pH appear to limit NMDAr-mediated excitotoxicity (Kaku et al., 1993). In 
the presence of ifenprodil (and CP-101,606), NMDAr sensitivity to protons is increased, 
providing an additional mechanism of antagonistic activity (Mott et al., 1998). It is likely 
that proton inhibition is a mechanism shared by phenylethanolamines in general (i.e., 
eliprodil and others), however this has yet to be demonstrated empirically.  
 
Ifenprodil has shown promise as a neuroprotectant during excitotoxic events, 
reducing edema and infarct volume in ischemia models (for review see Wang & Shuaib, 
2005), improving outcomes in reserpine & MPTP models of Parkinson’s (Nash et al., 
1999; Nash et al., 2000) and models of neuropathic pain (for review see Chizh & 
Headley, 2005). Such neuroprotection extends to in vitro ETOH WD-associated 
neurotoxicity (Mayer et al., 2002a), and it appears protective in vivo as well, based on 
attenuation of WD-associated seizure behaviors (Pawlak et al., 2005; unpublished data). 
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Eliprodil is an ifenprodil analogue, maintaining high specificity for NMDARs containing 
the NR2B subunit (Avenet et al., 1997), and has shown similar efficacy as a 
neuroprotectant in several models of excitotoxic injury (Toulmond et al., 1993; Bath et 
al., 1996; Reyes et al., 1998). Eliprodil’s neuroprotective action has been investigated in 
developmental models of insult; administration during acute WD rescues adulthood 
behavioral deficits in rodent FAS models (Thomas et al., 2004). 
 
Ifenprodil & eliprodil appear to have more modest inhibitory effects (compared 
with non-subunit selective compounds) synaptically, where diverse populations of 
NMDArs are found, including NR1/NR2A and NR1/NR2B diheteromers as well as 
NR1/NR2A/NR2B triheteromers (Tovar & Westbrook, 1999). However, extrasynaptic 
populations of NMDArs appear more homogenous, composed primarily of NR1/NR2B 
diheteromers (Tovar & Westbrook, 1999), and thus are strongly inhibited by ifenprodil. 
The synaptic localization of NMDArs appears to determine their opposing effects on 
gene regulation and neuronal survival; synaptic receptors induce anti-apoptotic effects, 
while Ca2+ entry via extra-synaptic NMDArs elicits loss of CREB function, reduced 
BDNF expression and ultimately mitochondrial dysfunction and cell death (Hardingham 
et al., 2002). Thus, NR2B-specific antagonism may exert its neuroprotection via 
extrasynaptic NMDAr inhibition, while largely preserving synaptic function. 
 
Additionally, ifenprodil appears to reduce ETOH consumption in a relapse model 
examining binge-like consumption following periods of forced abstinence, known as the 
alcohol-deprivation effect (ADE), a procedure also utilized in the current project (Sinclair 
& Senter, 1967). Furthermore, ifenprodil has been shown to block ETOH’s stimulatory 
effects (Broadbent, Kampmueller & Koonse, 2003), suppress ETOH WD effects in 
dependent rodents (Narita et al., 2000, Malinowska et al., 1999) and attenuate ETOH’s 
amnestic effects (Napiórkowska-Pawlak et al., 2000). Interestingly, NR2B-containing 
NMDArs appear to play an important role in behaviors related to other drugs of abuse. 
For instance, ifenprodil is known to block both CPP induction and expression for 
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morphine (Suzuki et al., 1999; Ma et al., 2006; Ma et al., 2007). Similarly, treatment with 
an antibody against NR2B subunits abolishes morphine-induced place preference, 
whereas antibodies against NR2A do not (Narita et al., 2000). These results suggest that 
examination of NR2B-specific compounds as anti-relapse agents for alcohol may inform 
research examining other drugs of abuse. 
 
While examinations of eliprodil and ifenprodil have returned promising results, 
and further implicated NR2B involvement in ETOH action, their clinical development 
has been slowed due to secondary effects including calcium channel blockade as well as 
alpha-adrenergic, 5HT1A, 5HT2, 5HT3 and sigma receptor inhibition (Chenard et al., 
1991; McCool & Lovinger, 1995; Biton et al., 1994). Although additional receptor 
system activation does not necessarily preclude clinical advancement, the aforementioned 
pattern of activation suggests complex cardiovascular and affective complications. 
 
5.7 CP-101,606 
Recent medication development efforts altered the composition of ifenprodil at 
several sites, producing a similar compound (see Figure 3), CP-101,606 (1S,2S)-1-(4-
hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (Pfizer). Radioligand 
binding studies have determined that CP-101,606 (CP) represents a distinct class of 
NR2B specific antagonists, which bind NR2B with high affinity only if the receptor is an 
NR2B/NR2B diheteromer (Chazot et al., 2002). This high degree of specificity is thought 
to limit its side effect profile in humans, suggesting its potential for clinical use in 
alcoholism. Additionally, this NR2B/NR2B specificity provides a unique pharmacological 
tool with which to investigate NR2B involvement in ETOH-associated relapse and 
neurotoxicity, and was thus selected as one of the compounds examined in the current 
project. 
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Figure 3. Molecular Structure of Ifenprodil and its Analogue, CP-101,606 
 
 
 
Thus far, CP has received limited attention in alcohol research, but has been used 
in several other fields. CP has shown efficacy as an antinociceptive agent (Boyce et al., 
1999), an anticonvulsant (Brackett et al., 2000) and has demonstrated anti-parkinsonian 
action (Nash et al., 2004; Steece-Collier et al., 2000). CP attenuates the effects of 
traumatic brain injury and focal ischemia in animal models (Okiyama et al., 1998; 
Okiyama et al., 1997; Tsuchida et al., 1997; Di et al., 1997; Kundrotiene et al., 2004) and 
protects hippocampal neurons from glutamate toxicity in vitro (Menniti et al., 1997), and 
of particular relevance to the current project, CP was used in a cortical cell culture model 
of ETOH WD, and demonstrated the ability to reduce excitotoxic effects in vitro (Nagy et 
al., 2004).   
 
Furthermore, our own work has demonstrated CP’s neuroprotective potential. 
Following chronic, neonatal ETOH exposure, a single administration of CP during 
withdrawal was able to attenuate a number of behavioral deficits reliably produced by 
this FAS model, including balance deficits, hyperactivity and learning & memory 
dysfunction (Lewis et al., submitted). 
 
In experimental mammals, CP seems to have few side effects; it neither impedes 
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motor performance (Boyce et al., 1999) or learning and memory as measured in Morris 
water maze (Guscott et al., 2003). In contrast to other NMDAr antagonists, it may 
enhance performance in cognitive tasks (Higgins et al., 2005). Importantly, CP has been 
used in several clinical studies, where it appeared well-tolerated (Johnson et al., 2003; 
Merchant et al., 1999); two in particular report positive reduction in the behavioral 
consequences of stroke and traumatic brain injury (Yurkewicz et al., 2005; Bullock et al., 
1999). Due to the mechanistic contributions of polyamine-sensitive NMDArs in 
neurotoxicity and relapse, and due to the noted safety and potential of CP-101,606, it was 
selected for use in the current project. 
 
5.8 Agmatine & Our Current Development Strategy: Novel Polyamine Modulators 
 Agmatine (decarboxylated L-arginine) was recognized approximately a century 
ago (Kossel, 1910) but identified in mammalian brain only within the last few decades 
(Li et al., 1994). The accumulated evidence suggests agmatine meets the criteria of a 
central modulator, and is currently considered a putative neurotransmitter (for review see 
Halaris & Plietz, 2007). Agmatine is synthesized in neurons (Reis & Regunathan, 2000; 
Iyo et al., 2006); is released presynaptically in a Ca+ dependent manner (Goracke-Postle 
et al., 2006); is disrupted by exogenous drugs (I1r antagonists; Wu, Su & Liu, 2006); is 
distributed in specific neuronal populations (i.e., hippocampal; Reis, Yang & Milner et 
al., 1998); has specific reuptake processes (Reis & Regunathan, 1998; Sastre, Regunathan 
& Reis, 1997), is enzymatically degraded (i.e., agmatinase; Sastre et al., 1996; Iyer et al., 
2002); and acts on receptors (e.g., Olmos et al., 1999; Piletz et al., 1995; Askalany et al., 
2005), effecting specific neuronal processes (e.g., nNOS inhibition; Demady et al., 2001). 
 
  The action of agmatine most relevant to the design of the current project involves 
its ability to act as an endogenous modulator of polyamine activity, functioning as a low 
potency NMDAr inhibitor, however it appears unique for several reasons, including its 
ability to inhibit or inactivate nNOS by up to 50%, at physiologically relevant 
concentrations (Auguet et al., 1995; Galea et al., 1996; Demady et al., 2001). NMDArs 
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and nNOS are both recognized for their contribution to glutamatergic neuroplasticity, 
suggesting agmatine may provide unique modulation of such neuroplasticity, unattainable 
via either NMDAr or nNOS-selective manipulation. The observation that agmatine is 
increased in hippocampus (~85%) following training of learning-dependent tasks (Morris 
maze) supports this suggestion, however the functional significance of increased 
agmatine is unknown. Furthermore, its unique NMDAr/nNOS profile suggests its 
prophylactic potential for excitotoxic damage (given the closely related involvement of 
both NMDAr and nNOS). Initially, reports of agmatine’s physiological concentration in 
CNS were low (pM-nM), however it is now recognized that acute stress or trauma may 
induce rapid agmatine synthesis, such that  >10 μM concentrations have been noted 
following insult (Aricioglu, Regunathan & Piletz, 2003). 
 
Of further significance, particularly in terms of its consideration as a therapeutic 
agent or lead compound, agmatine appears only a very weak channel inhibitor, with an 
IC50 of approximately 1 mM, significantly lower than other polyamine modulators 
ifenprodil or arcaine (IC50s of 500 nM and 5 μM, respectively). However, agmatine 
exhibits a Ki of ~15 μM for MK-801 binding in the presence of spermidine (100 μM; 
Ring, 2006), suggesting its ability to inhibit the NMDAr is polyamine-specific, at 
relevant concentrations.   
 
 Agmatine’s noted neuroprotective potential (e.g., Gibson et al., 2003; Gilad et al., 
1996; Lewis et al., 2007), anxiolytic effects (Lavinsky, Arteni, & Netto, 2003), 
attenuation of drug-associated conditioning (Wei et al., 2005), and reduction of ETOH 
WD symptoms (Uzbay et al., 2000) have generated interest in its clinical development for 
a range of diseases including schizophrenia (Uzbay et al., 2009), neuropathic pain (Onal 
et al., 2003) and substance abuse disorders. Recently, agmatine’s clinical efficacy as an 
antinociceptive agent was demonstrated in subjects suffering herniated lumbar disc-
associated radiculopathy (Keynan et al., 2010). While Kenyan & colleagues observed 
only mild-to-moderate side effects, concerns about uraemia (Piletz et al., 2003) and toxic 
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interactions with elevated potassium levels (Abe, Abe & Saito, 2003) are noted. One 
alternative to direct agmatine administration involves agmatinase inhibition (e.g., 
piperazine carboxamidine), a solution being explored currently (Huang et al., 2003). The 
current project has selected another strategy, using agmatine as a lead structure for the 
development of novel, higher potency, agmatine analogues. 
 
 To this end, we established a medications development screening project at the 
University of Kentucky, wherein novel molecules were synthesized in the Pharmaceutical 
Sciences Division of the College of Pharmacy and examined in molecular screens for 
polyamine inhibition. Compounds testing positive were then examined in simple cellular 
screens, followed by more complex tissue screens, simple behavioral screens and finally 
complex behavioral screens, all contingent on success in the previous tier of screening.  
 
 The primary molecular screen involved detection of [3H]MK-801 binding in 
membrane preparations, both in the presence and absence of spermidine. MK-801 is an 
open-channel ligand, whose Bmax is enhanced by approximately 75-100% when 
spermidine is added to the membrane preparation (Gibson et al., 2002). In this screen, 
compounds acting via competitive inhibition or steric hindrance display a monophasic 
binding curve, reducing [3H]MK-801 binding regardless of the presence or absence of 
spermidine. Compounds which display biphasic curves, such that at low concentrations 
[3H]MK-801 binding is only reduced in the presence of spermidine, are thought to 
display selectivity for polyamine inhibition. Over 1500 compounds have been screened in 
this manner, including a group of aryliminoguanidines. One member of this group, JR-
220 ([4-Chlorobenzylidenamino]-guanidine Hydrochloride; see Figure 4), was highly 
potent, with an IC50 of 3.6 μM. 
 
 
 
42 
 
 
Figure 4. Molecular Structure of Agmatine and its Analogue, JR-220 
 
 
 
  The neuroblastoma cell line SH-SY5Y expresses functional GLUergic cells and 
receptors, and is used in the current project to screen novel compounds for their ability to 
inhibit NMDA-induced 45Ca2+ entry. JR-220 (JR) was shown to inhibit calcium entry in a 
concentration-dependent manner with greater potency (10-100 μM) than agmatine (100-
500 μM). Neuroprotection of SH-SY5Y cells from NMDA insult (500 μM) at saturating 
concentrations of glycine and spermidine (10 μM and 100 μM, respectively), was 
assessed using the colorimetric assay, MTT. JR-220 significantly and concentration-
dependently (10-100 μM) reduced toxicity. This cell line was further used to screen for 
protection from ETOH withdrawal-associated damage (with identical concentrations of 
glycine and spermidine) after a 4-day exposure (180 mM). JR-220 (10-50 μM) 
demonstrated the highest neuroprotective capability in this screen. Importantly, when 
these SH-SY5Y experiments were conducted without adding exogenous spermidine, JR-
220 failed to show efficacy at aforementioned doses, consistent with the hypothesis that 
JR-220’s mechanism of NMDAr inhibition is polyamine-dependent. 
Given its success in the aforementioned molecular and cellular experiments, JR-220 was 
selected to continue advancement through our screening procedure and is the focus of 
the current work. 
  
Copyright © Ben Lewis 2011 
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Chapter 6. Hypotheses & Project Summary 
The hypothetical framework for the current project conceptualizes the behavioral and 
cellular alterations associated with chronic ethanol consumption as being driven in large 
part by persistent alterations in glutamatergic tone and function, and being reversible via 
NMDAr antagonism.  
HYPOTHESIS 1:
Hypothesis 1a) JR-220 will reduce both in vitro and in vivo (convulsion) indications of 
 Compounds which selectively inhibit polyamine stimulation of the 
NMDAr will perform positively in predictive screens for 
attenuation of a wide range of ETOH-associated effects and 
behaviors. Specifically: 
     neurotoxicity 
Hypothesis 1b) JR-220 will reduce cue-conditioned withdrawal behavior 
Hypothesis 1c) JR-220 will reduce drinking behaviors associated with both positive and 
  negative reinforcement, including stress, relapse, and binge screens. 
HYPOTHESIS 2:
Hypothesis 2a) CP-101,606 will reduce both in vitro and in vivo (convulsion) indications 
of neurotoxicity. 
 Compounds which selectively inhibit polyamine stimulation in a 
subset of NMDArs containing NR2B/2B diheteromers will be 
sufficient for positive performance in our predictive screens. 
Specifically: 
Hypothesis 2b) CP-101,606 will reduce drinking behaviors associated with both positive 
and negative reinforcement, including stress, relapse, and binge screens. 
HYPOTHESIS 3:
Hypothesis 3a) JR-220 will reduce consumption in the ‘Drinking in the Dark’ model. 
 Selective polyamine inhibitors which perform positively in our 
predictive screens will demonstrate efficacy in standardized, 
established models of pathological ETOH consumption. 
Specifically: 
Hypothesis 3b) CP-101,606 will reduce consumption in the ‘Drinking in the Dark’ 
model. 
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 Experiments presented here were conducted in the context of a drug discovery 
project, designed to identify novel compounds with the potential to reduce withdrawal 
severity, neurotoxicity and relapse risk. The current work presents a subset of screens 
from this project. The included screens have been validated with relevant drugs (i.e., 
acamprosate, topiramate, memantine), with one notable exception (see below). Screens 
include a complex organotypic hippocampal culture screen designed to assess 
neuroprotective potential (Experiment 1), a simple behavioral screen designed to assess 
withdrawal severity (Experiment 2) as well as several more complex behavioral screens 
designed to examine cue-conditioning during withdrawal (Experiment 3), relapse-like 
drinking behavior (Experiment 4), stress-associated consumption (Experiment 5) and 
binge-like drinking behavior (Experiment 6). Though not directly examining drinking 
behavior, a final behavioral screen (Experiment 7) was included to assess potential 
anxiety-related and/or activity-related effects of the compounds tested. Finally, a model 
of binge-like drinking was utilized to further examine screening results (Experiment 8). 
 
 The primary compound of interest for the current project is JR-220, a modulator 
of polyamine enhancement of NMDAr function. Data generated from the examination 
of JR-220 in Experiments 1-6 will directly test Hypothesis 1. CP-101 was examined both 
due to its therapeutic potential as well as its unique pharmacological profile, which may 
help illuminate the contribution of NR2B-containing NMDArs to the behaviors examined 
here. Although only examined in Experiments 1, 2, and 6, data generated from these 
experiments will directly test Hypothesis 2. Based on the results of these screens, we 
utilized a well-recognized model of binge-like consumption (Experiment 8) to further 
explore these compounds. While Experiment 8 will directly test Hypothesis 3, it does not 
represent a complete examination, but rather the first in a series of planned explorations, 
the entirety of which are beyond the scope of this dissertation. 
 
 
 
Copyright © Ben Lewis 2011 
45 
 
 
Chapter 7. Methods, Results & Discussion (By Experiment) 
 Experiments presented here represent screens which were developed based on 
several well-established models of ETOH intake behavior, as well as some lesser-known 
paradigms (e.g., Experiment 3). We use Sprague-Dawley rats as well as Swiss Webster 
and C57BL6J mice. Species/strains were selected based on either established literatures 
suggesting the appropriateness of our chosen species/strains (Experiments 1,2,5 and 6) or 
the experiences of our group in establishing these paradigms (Experiment 3). The 
exception is Experiment 4; Wistar rats are the most common strain used (P rats are also 
common) in the model from which this screen was established; Sprague-Dawley rats 
were selected for pragmatic reasons (our group maintains an established Sprague-Dawley 
breeding program and has extensive experience with this strain). However, using well-
established methods (discussed below) we have repeatedly demonstrated the paradigm’s 
utility with this strain. The information above is described in Table 1. 
Table 1. Species/Strain Use by Experiment 
Exp. Screen/Model Species/Strain (Strain-specific) References 
1 Hippocampal Slice Culture 
(OHSC) 
Rat: Sprague-Dawley            
(In vitro) 
(e.g., Stoppini et al., 1991; Gibson et al., 2003; 
Prendergast et al., 2000; Stepanyan et al., 
2008; Noraberg and Zimmer, 1998) 
2 Handling-Induced 
Convulsion (HIC) 
Mouse: Swiss Webster  (e.g., Farook et al., 2007; Stepanyan et al., 
2008; Crabbe et al., 1980) 
3 Conditioned Withdrawal in 
Elevated Plus Maze (EPM) 
Mouse: Swiss Webster (Farook et al., 2007; Wilson et al., 1998*; Cole 
et al., 1999*; Cole et al., 2000*) 
 
* used TO Mice, derived from Swiss Websters.  
4 Alcohol Deprivation Effect 
(ADE) 
Rat: Sprague-Dawley * The use of Sprague-Dawleys is atypical; 
Wistars and P rats are used most commonly.  
5 Stress-Associated Drinking Mouse: C57BL/6J (Farook et al., 2009; Lopez et al., 2011) 
6/8 Drinking in the Dark (DID) Mouse: C57BL/6J (e.g., Rhodes et al., 2005; Rhodes et al., 2007; 
Moore & Boehm, 2009; Gupta et al., 2008) 
7 Open Field (OF)                  a All species/strains (e.g., Rubin et al., 2008; Wellmann et al., 
2011) 
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 Preclinical models (both in vivo and in vitro) have three basic measures of 
validity. Construct validity describes the extent to which the physiological mechanisms or 
underlying pathophysiologies are similar between the cellular/animal models and 
humans. Face validity describes the extent to which the model mimics the behaviors or 
symptoms exhibited in the human disease. Construct and face validities are historically 
the models more heavily weighted when considering the usefullness of a particular 
model. However, for the purposes of drug discovery, predictive validity, or the ability to 
predict a drug’s action and/or efficacy in humans, is considered critical. The challenge for 
establishing predictive validity is generally the need for an efficacious pharmacotherapy 
in humans to use as a benchmark with which screen results may be compared. While 
these data are not shown, Experiments 1-5 were previously validated with several 
relevant compounds, including ifenprodil, memantine, and most importantly, 
acamprosate, which was considered a ‘best-in-class’ reference drug both for its efficacy 
in treating human alcoholics as well as its putative mechanisms of action, which most 
closely resemble (compared to other FDA-approved drugs) those of our compounds. 
In the development of our screens and screening procedure, predictive validity 
was the most strongly considered, since high throughput screening with strong predictive 
validity should have the greatest power to identify potential compounds of interest, which 
can then be tested more thoroughly in models with face and construct validity (this idea is 
well represented in our transition from simple screens to Experiment 8). Designations of 
‘screen’ and ‘model’ are particularly challenging in the current work, which utilizes both. 
In the context of this project, ‘screen’ is used to describe an experiment whose primary 
function involves prediction of, rather than direct evidence for, efficacy. Experiment 2 
(described in detail below) illustrates this concept; the elicitation of convulsions during 
artificially exacerbated ETOH withdrawal fails to resemble clinically-manifested 
behaviors, but predicts modulatory actions at the receptor level which resemble current 
NMDAr-directed pharmacotherapies. It is thusly considered a screen, rather than a 
model. While Experiments 2 and 8 provide clear examples of screens and models, 
respectively, other experiments are less easily dissociated, and although selected for their 
predictive validity, offer significant face and construct validities. 
47 
 
 
Experiment 1: Organotypic Hippocampal Slice Culture (OHSC) 
 Although numerous in vitro models have been utilized to examine 
neuroprotection from excitotoxic insult, our complex in vitro screen required a paradigm 
which could efficiently characterize the effect of pharmacological agents in live brain 
tissue. The organotypic hippocampal slice (OHSC) procedure uses a brain area known to 
be particularly vulnerable to ETOH, and is conducive to the type of screening procedure 
used here. The procedures described here were originally developed by Stoppini and 
colleagues (1991), and produce hippocampal slices containing live, intact neurons and 
glia, maintaining a high level of complex neuronal connection and surviving in an 
apparently healthy state for extended periods of time (Stoppini et al., 1991). This method 
has been used extensively by our group (e.g., Gibson et al., 2003; Prendergast et al., 
2000; Stepanyan et al., 2008) and others (e.g., Noraberg and Zimmer, 1998) to 
investigate chronic ETOH exposure and WD. Importantly, the OHSC screen has been 
validated with a number of highly relevant compounds. Ifenprodil (Gibson et al., 2003), 
memantine (Stepanyan et al., 2008) and acamprosate (Mayer et al., 2002a) have all been 
shown to reduce excitotoxic insult during/following ETOH withdrawal in this model. 
Furthermore, the contribution of polyamines to damage in this paradigm is established, as 
evidenced by attenuated damage following DFMO treatment (Gibson et al., 2003) and 
exacerbated damage following exogenous polyamine application (Mayer et al., 2002b), 
suggesting its particular sensitivity as a screening tool for polyamine modulators.  
 
 While described in detail below, the procedure involves extracting hippocampi 
from rat pups, plating the slices in hormone/nutrient-rich media and chronically exposing 
the slices to ETOH. Upon removal of the ETOH, significant CA1 toxicity occurs. In the 
studies presented here, various concentrations of JR-220 and CP-101,606 were examined 
for their ability to prevent this withdrawal-associated excitotoxicity. In all conditions 
slices were exposed to exogenous NMDA, either a toxic dose (20 μM) or a mild dose (5 
μM), which does not induce significant toxicity (unpublished data). This mild dose was 
used to model excessive GLU influx from hippocampal afferents during WD. The 
competitive NMDAr antagonist MK-801 was also included as a treatment. [5 μM 
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NMDA] alone was used as a negative control, while [20 μM NMDA] and [5 μM NMDA 
+ MK-801] provided positive controls (indicating maximal toxicity and protection, 
respectively). Cell death was indexed by fluorescence of propidium iodide (PI), which 
binds DNA, entering via compromised cell membranes (Zimmer et al., 2000). This index 
of cell damage has been validated by several other markers (Wilkins et al., 2006). 
Specifically, we hypothesized that both CP and JR would reduce ETOH WD-associated 
PI fluorescence in CA1, a direct measure of cellular damage. 
 
Subjects 
  Sprague-Dawley rats used in the current project were born in our breeding 
facility at the University of Kentucky (UK) Psychology Department. Parent animals were 
obtained from Harlan Labs (Indianapolis, IN). Animals were mated nightly, and the 
presence of a seminal plug the following morning indicated copulation had occurred. 
Pregnant females were individually housed in plastic cages in a temperature controlled 
nursery (70±3° F) on a 12:12 light:dark cycle (on at 0700h, off at 1900h) with food and 
water provided ad libitum. On the day following birth (PND1) litters were culled to 10 
animals, maintaining a 1:1 sex ratio when possible. All research was conducted in 
accordance with the guidelines of the National Institute of Health Guide for the Care and 
Use of Laboratory Animals (NIH Publications No. 80-23, 1996) and approved by the 
University of Kentucky Institutional Animal Use and Care Committee. 
 
Hippocampal Extraction & ETOH Exposure 
 PND8 Sprague-Dawley rat pups were used in all OHSC experiments. Pups from 
11 litters were sacrificed (3 males/3 females, per litter) via rapid decapitation, brains 
aseptically removed, and transferred to ice-cold dissecting media [Minimum Essential 
Medium (MEM; Gibco BRL, Gaithersburg, MD), 25 mM HEPES (ATCC, Manassas, VA), 
200 mM L-glutamine (Invitrogen, Carlsbad, CA), 50 μM streptomycin/penicillin (ATCC, 
Manassas, VA)]. Following removal of the meninges, hippocampi were removed, sliced 
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coronally at 200 μm (McIllwain Tissue Chopper; Campden Instruments Ltd., Lafayette, 
ID) and plated in triplicate onto 0.4 μm Biopore membranes (Millipore, Marlborough, 
MA). Membranes were suspended in 1 ml culture media [dissecting media, 36 mM 
glucose, 25% Hanks’ balanced salt solution (HBSS; Gibco BRL, Gaithersburg, MD), 
25% heat-inactivated horse serum (HIHS; Sigma, St. Louis, MO)] using six-well plates. 
 
 Plates were incubated at 37 °C in a 5% CO₂/21% O₂/74% N₂ medical grade gas 
composition for 5 days in vitro (DIV) to allow affixture to the membrane. On the fifth 
day in vitro (DIV 5) the plates were treated with new culture medium, with half exposed 
to 100mM ETOH. This media change was repeated on DIV 10. Between media changes, 
plates were housed in airtight plastic chambers with humidity and ethanol vapor 
concentrations maintained by placing 50 ml of 100 mM ETOH into the chambers; control 
chambers received 50 ml of water instead of ETOH. The chamber environment was filled 
with an identical composition of medical grade gas before being sealed and placed back 
into the incubator. 
 
NMDA Challenge & ETOH Withdrawal 
  On DIV 15, a final media change was conducted, with ETOH-free media 
containing PI (2.5 μg/ml, Molecular Probes, Eugene, OR) added to each well. Well 
treatments included 5 μM NMDA (5N), 20 μM NMDA (20N; used as a negative control), 
5 μM NMDA + MK-801 (20 μM; used as a positive control) and 5 μM NMDA + Drug 
(e.g., JR). In order to reduce litter effects and facilitate comparison between groups, 
treatments were divided across subjects such that no treatment was repeated within a 
single subject in either the ETOH or control condition. Figure 5 illustrates an example of 
assigned treatments in a particular culture. 
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Figure 5. Treatment Distribution Within a Single Culture 
 
Imaging & Analysis  
 PI uptake was visualized at 5x objective using a Leica DMBIRM microscope (W. 
Nuhsbaum Inc.; McHenry, IL) fitted for fluorescent detection (Mercury-arc lamp), and 
imaging software (SPOT Advanced, version 4.0.2, W. Nuhsbaum Inc.; McHenry, IL). PI 
fluorescence was analyzed using Image J, v1.29x (National Institutes of Health, 
Bethesda, MD). Dentate gyrus (DG), and cornu ammonis regions 1 (CA1) and 3 (CA3) 
were all analyzed. For each slice, background fluorescence was subtracted from the 
region of interest prior to analysis. Fluorescence was recorded in arbitrary units, then 
converted to percent of control, facilitating comparison across multiple cultures and 
controlling for variation between litters. Two-way analyses of variance (ANOVAs) were 
conducted (Sex x Treatment) on a regional basis. If no effect of sex was detected, sex was 
collapsed in further analyses. If the initial ANOVA was significant, planned comparisons 
(Fisher’s protected t) were conducted to compare treated slices to their appropriate 
controls (ETOH-exposed or ETOH-naïve). Experiments with JR utilized six litters 
(N=217), distributed across 20 treatment groups, as depicted in Table 2. Experiments 
with CP utilized five litters (N=177), distributed across 16 treatment groups, as depicted 
in Table 3. 
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Table 2. JR-220 Treatments & Subjects        Table 3. CP-101 Treatments & Subjects 
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JR-220 Results 
Images of representative slices are presented in Figure 12, following these results. 
CA1 
 In CA1, administration of JR reduced fluorescence in ETOH-treated slices at all 
concentrations. No toxicity in ETOH-naïve slices was noted. The initial overall analysis 
revealed an effect of TREATMENT, F(18, 193)=27.633, p<.001, in CA1. No effect of 
sex was detected. Planned comparisons (Fisher’s protected t) revealed that in ETOH-
treated groups, fluorescence was significantly reduced by MK and all concentrations of 
JR (p<.001, p<.001, p=.003, p<.001, p=.001, p=.010, p=.002, p=.021, p<.001, 
respectively) . Fluorescence was increased following 20 μM NMDA treatment (p<.001), 
as expected. A second set of planned comparisons conducted among ETOH-naïve slices 
indicated differences only in the positive and negative control conditions; increased 
flouresence following 20 μM NMDA treatment (p<.001) and decreases following MK-
801 treatment (p=.004) were noted. Figure 6 depicts PI uptake in the CA1 region relative 
to controls. 
Figure 6. JR-220 in CA1 
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CA3 
 In CA3, administration of JR reduced fluorescence at the lowest dose, while 
appearing toxic at 100 μM. An overall ANOVA revealed a main effect of TREATMENT, 
F(18, 193)= 6.301, p<.001, in CA3. No effect of sex was detected. Planned comparisons 
(Fisher’s protected t) revealed that fluorescence differed between the ETOH control 
group and four other ETOH-exposed groups. In the case of MK-801 (p=.013) and 50 μM 
JR (p=.023) this difference reflected reduced PI uptake, while in the cases of 20 μM 
NMDA (p<.001) and 100 μM JR (p=.024), increased uptake was observed. Among 
ETOH-naïve slices, 20 μM NMDA increased uptake (p<.001). Figure 7 depicts PI uptake 
in the CA3, relative to controls. 
 
Figure 7. JR-220 in CA3 
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DG 
 In DG, 100 μM JR was associated with increased fluorescence, no other effects 
were noted. An overall ANOVA revealed a main effect of TREATMENT, F(18, 193)= 
4.982, p<.001, in DG. No effect of sex was detected. Planned comparisons (Fisher’s 
protected t) revealed only a difference between ETOH-exposed 20 μM NMDA slices and 
controls (p=.001). Among ETOH-naïve slices 100 μM JR was associated with increased 
fluorescence (p=.018), as was 20 μM NMDA (p<.001). Figure 8 depicts PI uptake in the 
DG, relative to controls. 
 
Figure 8. JR-220 in DG 
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CP-101,606 Results 
CA1 
 In CA1, administration of CP reduced fluorescence in ETOH-treated slices at low 
concentrations, but was associated with toxicity at higher concentrations in both ETOH 
and ETOH-naïve groups. The overall ANOVA revealed a main effect of TREATMENT, 
F(14, 155)=21.338, p<.001, in the CA1. No effect of sex was detected. Planned 
comparisons (Fisher’s protected t) revealed decreased PI uptake in 10 nM CP (p<.001), 
25 nM CP (p<.001) and MK-801 (p<.001) treated slices, relative to ETOH controls, and 
increased PI uptake in 75 nM CP (p=.022) and 20 μM NMDA-treated slices (p<.001). 
Among ETOH-naïve controls, increased uptake among 20 μM NMDA-treated (p<.001), 
50 nM CP-treated (p=.003 ) and 75 nM CP-treated  (p<.001) slices was noted. Figure 9 
depicts PI uptake in the CA1, relative to controls.  
 
 
Figure 9. CP-101,606 in CA1 
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CA3 
 No effects of CP were noted in CA3. An overall ANOVA revealed a main effect 
of TREATMENT, F(18, 193)= 8.864, p<.001, in CA3. No effect of sex was detected. 
Planned comparisons (Fisher’s protected t) revealed fluorescence differences between 
ETOH controls and ETOH+20 μM NMDA (p<.001), only. Among ETOH-naïve controls, 
only increased uptake among 20 μM NMDA-treated slices (p<.001) was noted. These 
results are depicted in Figure 10, below. 
 
Figure 10. CP-101 in CA3 
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DG 
 No effects of CP were noted in DG. An overall ANOVA revealed a main effect of 
TREATMENT, F(18, 193)= 8.290, p<.001, in DG. No effect of sex was detected. 
Planned comparisons (Fisher’s protected t) revealed fluorescence differences between 
ETOH controls and ETOH+20 μM NMDA (p<.001), only. Among ETOH-naïve controls, 
only increased uptake among 20 μM NMDA-treated slices (p<.001) was noted. These 
results are depicted in Figure 11, below. 
 
Figure 11. CP-101 in DG 
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Figure 12. Representative Slices From Select Treatment Groups 
including a) Control, b) ETOH, c) 20 μM NMDA, d) 50 μM JR-220 , e) 
25 nM CP-101, and f) 20 μM MK-801 . 
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OHSC Discussion 
 Results from the OHSC screen demonstrated the neuroprotective potential of both 
compounds. Among cultures examined in the JR experiments, the untreated, ETOH-
exposed slices demonstrated increases in PI fluorescence of approximately 70% in CA1. 
At all concentrations examined, JR-220 reduced fluorescence. Comparison among 
ETOH-naïve slices indicated no associated toxicity in controls at any concentration of JR. 
Results from the CA3 region were slightly perplexing; ETOH was associated with a 
moderate increase in PI fluorescence. The lowest concentration of JR (50 μM) appeared 
to reduce ETOH-associated toxicity; while 100 μM significantly increased it. This higher 
dose was also associated with toxicity in ETOH-naïve cultures. A similar pattern of 
effects were noted in DG, however only the increased toxicity among ETOH-naïve slices 
treated with 100 μM JR retained significance. These results are somewhat perplexing, in 
that JR did not appear toxic in the CA1, considered particularly sensitive to polyamines 
and polyamine manipulation (Butler et al., 2010), but did appear toxic in less sensitive 
regions. While these findings should be interpreted cautiously (given the low number of 
subjects exposed to the 100 μM concentration), they may suggest additional mechanisms 
of JR-220 action, and potentially an unanticipated toxic mechanism (discussed in greater 
depth in the final discussion section). 
 
 Among cultures examined in the CP-101 experiments, the untreated ETOH-
exposed slices demonstrated increases in PI fluorescence of approximately 90% in CA1. 
The results from CA1 were suggestive of a U-shaped curve; low doses (5 nM) were 
ineffective at reducing toxicity, moderate doses (10 and 25 nM) were efficacious, while 
higher doses (50 and 75 nM) indicated an exacerbation of toxicity. These effects were 
mirrored in ETOH-naïve slices (50 and 75 nM concentrations increased fluorescence). 
While the high selectivity of CP-101 is suggested to limit its inherent toxicity and side 
effect profile, the NR2B class of NMDAr antagonists has been associated with toxic 
effects in NR2B-rich nuclei (Parsons, Danysz & Quack, 1998). In contrast to those 
cultures in which JR was examined, no ETOH-associated increases in CA3 or DG were 
noted among control slices in these experiments. Furthermore, no evidence of CP-
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associated toxicity was noted among either ETOH-exposed or naïve slices in either CA3 
or DG. The contrast between marked CA1 toxicity is likely due to the noted 
concentration of NR2B subunits in CA1, and suggests low, if any, expression of 
NR2B/2B stoichiometries in either DG or CA3. 
 
These results are consistent with our hypotheses that inhibitory polyamine modulation, 
whether NR2B-specific or not, would attenuate excitotoxic injury. The success of both 
compounds in this screen (at multiple doses) indicated their potential for neuroprotection, 
thus both compounds were advanced to simple behavioral screening. 
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Experiment 2: Handling-Induced Convulsion (HICs) 
 Examining seizure-susceptibility in ETOH-exposed rodents via handling has been 
used as a behavioral model of withdrawal severity for some time. The HIC procedure was 
first developed by Goldstein & Pal (1971), and has been utilized by a variety of groups 
since (e.g., Crabbe et al., 1980; Grant et al., 1990; Wilson & Little, 1998). HICs are 
precipitated by removing the animal from its home cage by holding the tail, then gently 
spinning it. HIC seizures are graded in their severity, producing a scorable response, 
facilitating their use as both an indicator of CNS hyper-excitability and a sensitive 
assessment tool. However, many HIC studies have used either extended periods of 
exposure or ETOH inhalation chambers. The current experiment utilizes an abbreviated 
procedure, designed to more efficiently screen compounds for anticonvulsant effects. 
Instead of prolonged or inhalation exposure, our procedure utilizes an ETOH 
dehydrogenase inhibitor (4-methylpyrazole; 4MP), administered concurrently with 
ETOH. While pyrazole has been used in this manner previously (e.g., Terdal & Crabbe, 
1994), our lab has demonstrated that with its use, convulsant activity may be precipitated 
after only three days of i.p. ETOH exposure (Farook et al., 2007). 
 
 NMDAr antagonism induces known anticonvulsant effects during ETOH WD 
(Rossetti & Carboni, 1995). Our abbreviated screening procedure has been validated with 
numerous relevant compounds; reductions in HICs associated with acamprosate (Farook 
et al., 2008), topiramate (Farook et al., 2007) memantine (Stepanyan et al., 2008) and 
ifenprodil (unpublished data) have all been demonstrated. Moreover, while our screen 
uses Swiss Webster mice, reductions in WD-associated seizures appear across other 
strains/species (e.g., memantine; Bienkowski et al., 2001; Kotlinska, 2001). 
Specifically, we hypothesized that following chronic ETOH+4MP treatments, JR and CP 
would reduce withdrawal-associated handling-induced convulsion. 
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Subjects 
 Male Swiss Webster mice (Harlan, IN) weighing 29±3 g (approximately 15-18 
weeks) were housed 3/cage. A 16/8 light/dark cycle (on at 0600h, off at 2100h) and ad 
libitum chow and water were maintained throughout the experiment. Thirty-five mice 
were used per experimental replication, divided into 7 groups of 5 animals, each. Three 
experimental replications were conducted for each drug tested. 
 
ETOH & Drug Treatments 
 A 2.5 g/kg ETOH solution was administered (i.p.) daily (1300 h), using an 
injection volume of 10 ml/kg, for three consecutive days. 4MP (9 mg/kg; Sigma-Aldrich, 
USA), an ETOH dehydrogenase inhibitor, was co-administered with saline or ETOH. 10 
h following the third and final administration of ETOH, animals were administered 
treatment dissolved in saline and injected at 10 ml/kg (i.p.). Thirty minutes following 
drug administration, animals were assessed for convulsive activity.  
 
 A range of JR-220 doses was examined in this paradigm; the first replication 
utilized low doses (1-15 mg/kg), and when no obvious behavioral perturbances were 
noted the dose was increased (10-40 mg/kg) for subsequent replications. Since we had 
greater confidence in our selection of active doses for CP based on available animal 
literature, all three replications utilized the same 1-20 mg/kg range. 
 
HIC Scoring 
 Assessment of seizure susceptibility was performed by gently lifting each mouse 
by the tail and observing convulsive behavior; if no convulsions were present, they were 
precipitated by gently spinning the animals 360 degrees clockwise, then 
counterclockwise, using the thumb and forefinger, for a period of 5 sec, after which 
convulsions were assessed. Scoring was based on a modified scale (Wilson & Little, 
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1998) and is described in Table 4. Scores indicated severity, with 0 indicating no 
convulsive activity, 3 indicating clonic convulsion, and 4 indicating convulsion (prior to 
spin) upon tail-lift. All scoring was conducted by an experimenter blind to treatment 
condition. 
 
Table 4. Handling-Induced Convulsion Assessment Scale 
 
 
Blood Sampling 
Blood samples were collected following the 3rd day of alcohol exposure and 
analyzed using the Analox AM1 Alcohol Analyzer (Lunenberg, MA). Animals received 
either ETOH alone or in combination with 4MP. Approximately 8 animals were used for 
each treatment condition, divided into two groups, such that each group was sampled at 
three exclusive time points (i.e. group 1 sampled at 30, 120, 480 min; group 2 sampled at 
60, 240, 600 min). Blood was gathered by removing the tip of the tail (1 mm) and 
collecting approximately 40 µL of tail blood in heparinized tubes. Tubes were 
centrifuged and plasma frozen for analysis. Blood was collected at 30, 60, 120, 240, 480 
and 600 min following injection, and again at 24 h. A separate group of animals were 
used for the BEC analyses.   
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Statistical Analysis 
  Each compound was analyzed in three experimental replications (N’s=105). HIC 
scores were converted to a percentage of the ETOH-naïve group average, to reduce 
variability and allow for comparison across replications. Scores were analyzed using one-
way ANOVA (treatment). Post-hoc comparisons were conducted using Dunnett’s test, 
comparing each group to the ETOH controls. BEC analyses were conducted using 
repeated measures ANOVA, with 4MP exposure as the between-subjects variable. 
 
Results: BECs 
 4MP increased BECs at two time-points. An initial repeated measures ANOVA 
(4-MP x TIME) revealed an interaction of time and treatment. T-tests conducted at each 
time point indicated significantly higher blood ethanol at 120 and 240 minutes following 
injection (p’s <.001) showing the differential ethanol exposure caused by the addition of 
4MP  (or something to provide the reader with what it means in a simple sentence or 
two). Blood ethanol in both groups was reduced to minimal levels by eight hours, post-
injection. These results are depicted in Figure 13.  
Figure 13. BEC as a Function of Time and 4MP Treatment 
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JR-220 HICs 
  JR-220 reduced HIC behaviors at doses ranging from 10-40 mg/kg. HIC scores 
from all three JR-220 replications were converted to percentages of the average control 
group’s score, and combined into a single dataset. The ANOVA indicated a significant 
effect of treatment, F(7, 79)= 4.297, p=.001. Dunnett’s tests detected differences between 
ETOH controls and 10 (p=.019), 15 (p=.010), 20 (p=.001), 30 (p=.002) and 40 (p=.001) 
mg/kg doses of JR-220. These results are depicted in Figure 14. 
 
Figure 14. JR-220 HICs, Percent Control Values 
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CP-101,606 HICs 
 CP-101 reduced convulsions at all doses tested. The ANOVA indicated an effect 
of treatment, F(4, 90)= 15.444, p<.001. Dunnett’s tests indicated signficant reductions in 
HICs for all doses of CP tested, including 1 (p<.001), 5 (p<.001), 10 (p<.001) and 20 
(p<.001) mg/kg. Results are depicted in Figure 15. 
 
Figure 15. CP-101,606 in HICs, Percent Control Values 
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HIC Discussion 
 In the HIC tests, both compounds were found to be effective at reducing 
convulsive behavior during ETOH withdrawal, across a range of doses. JR-220’s 
attenuation of HICs was dose-dependent, with 1 and 5 mg/kg doses failing to 
significantly reduce the behavior. However, the trend for reduction noted at 5 mg/kg and 
the striking similarity in the means and SEs between the 5 and 10 mg/kg groups suggest 
that the 5 mg/kg dose would have achieved significance had the subject representation 
been equivalent across groups (5 mg/kg n=5; 10 mg/kg n=15).  
 
Prior to analyzing compounds in this screen, BEC curves were generated to establish 4-
MP’s elevation and potentiation of ETOH in blood. While a clear increase in peak BEC 
was noted following 4MP, as was an increase at the 4 hr measurement, increases in the 
duration of detectable ETOH in blood may be inferred due to the linear metabolism of 
ETOH (but are not directly demonstrated in this experiment); BECs returned to 0 
between our 4 and 8 hr measurements. Importantly, 4MP has been tested in ETOH-naïve 
animals, with no discernable effect on HIC scores (Farook et al., 2007). 
 
 CP-101,606 appeared to dose-dependently reduce HICs at every dose tested, 
demonstrating slightly higher potency relative to JR. This is not surprising, when 
efficacious concentrations in the OHSC experiment are considered (10 & 25 nM CP vs. 
50-125 mM JR). The magnitude of CP effects at equivalent doses also appeared greater. 
However, NR2B-containing NMDArs are thought to uniquely contribute to 
seizure/convulsive behaviors, and the implication of NR2B involvement in excitotoxicity 
(thought to underlie convulsive behavior) is well established. Thus, CP’s potency should 
again be unsurprising. While the data are not presented in the current work, CP’s potency 
appeared approximately equivalent to that of the NR2B-specific antagonist ifenprodil.  
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 A parsimonious interpretation of these results suggests that ETOH WD-associated 
seizure susceptibility is under at least partial control by NR2B subunits. Speculatively, 
the observed reductions in convulsive behavior, which at higher doses of both 
compounds were well below that of the ETOH-naïve animals, corroborates evidence that 
NR2B antagonists have potent anticonvulsant potential (e.g., Wlaz et al., 1999), and 
suggests that JR-220 shares agmatine’s noted anticonvulsant properties (Feng et al., 
2005). The success of both compounds in this screen provide further (albeit indirect) 
evidence for neuroprotection. Taken together, OHSC and HIC results suggested that both 
compounds possessed the potential to blunt withdrawal effects and protect from 
withdrawal-associated damage.  
These results support the hypothesis that inhibitory polyamine modulation will reduce 
withdrawal-associated handling-induced convulsion. 
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Experiment 3: Conditioned Pseudo-Withdrawal in the Elevated Plus Maze (EPM) 
 Opponent-process theory, mentioned in previous sections, conceptualizes drug 
effects (a-processes) as being mediated by compensatory physiological responses 
designed to maintain homeostasis (b-processes). Following chronic use, it is hypothesized 
that b-processes are induced by drug-associated cues and are thought to trigger drug-
opposite effects similar to withdrawal, increasing the negative reinforcing value of the 
drug and potentially leading to resumption of use. One important capability of potential 
anti-relapse treatments, therefore, is the ability to blunt responses to drug-associated cues 
during acute and protracted withdrawal. 
 
 While several relapse models have utilized ETOH-associated conditioned cues, 
the behavioral responses of interest are generally consummatory in nature, and therefore 
unable to answer questions about inhibition of ETOH-conditioned behavior, since the 
reinforcing effects of ETOH confound interpretation. The current screen was developed 
as a solution, and involves repeated pairing of ETOH with an ETOH-associated 
environment (an elevated-plus maze; Cole et al., 1999). Following repeated ETOH-maze 
pairings, a vehicle injection appears to induce conditioned abstinence behavior. This 
behavior is not elicited when the vehicle injection is delivered in a non-conditioned 
environment, when ETOH is on board, or when previously ETOH-naïve animals are 
administered ETOH in the plus maze. The primary abstinence behavior is termed 
‘stretched-attend’ posture, and involves extension of the forepaws and upper body 
(“stretch”), without forward movement. An alternate interpretation of this behavior is that 
it could indicate cued behavior resulting from positive interoceptive or internally 
rewarding feelings (an ‘incentive salience’ interpretation, rather than an ‘opponent-
process’ interpretation), indicating pleasure derived from the conditioned stimulus. 
However, when naltrexone was examined in this model, no attenuation of the stretched-
attend behavior was noted (Cole et al., 2000). In contrast, acamprosate (thought to relieve 
negative affect) was effective in reducing these behaviors (Cole et al., 2000), suggesting 
their association with negative affect or conditioned withdrawal. The demonstration of 
acamprosate’s efficacy in this model suggests strong predictive validity for its use as an 
70 
 
 
anti-relapse screen. Furthermore, while potentially any novel environment could be 
conditioned in this manner, the use of the elevated plus maze (EPM) allows for the 
additional examination of secondary effects of the compounds, including the examination 
of exploratory and anxiety-related behaviors. 
Specifically, we hypothesized that JR would reduce stretched-attend responses to an 
ETOH-conditioned environment (the elevated plus maze). 
 
Apparatus 
 The EPM was constructed from black Plexiglas, with two arms enclosed by walls 
(30 x 17 x 6 cm) and two open (unprotected) arms (30 x 6 cm). The maze was elevated 
44.5 cm above the floor. 
 
Procedure 
 Mice were divided into 4 groups (n’s=5-6) in which 2 groups received saline and 
2 received i.p. ETOH injections (1.75 g/kg). Animals were injected daily for 9 days, 
between 1200h and 1300h. 10 min after injections, they were placed on the center of the 
plus maze test apparatus for a 5 min conditioning session (Cole et al., 2000; Farook et al., 
2007). On day 10, subjects received either saline or a 20 mg/kg dose of JR. A 40 mg/kg 
group was also included, however the generated data were not interpretable due to 
sedative effects and thus were removed from the dataset; see discussion for further 
details. Thirty minutes following injection they were then placed in the center of the 
maze. On day 10, behavior in the maze was recorded for a 5 min test session. The 
dependent variables included time spent in the open vs. closed arms, total number of arm 
entrances and number of stretched-attend postures (defined as when the subject stretches 
forward with its forepaws without actually moving its hind paws) (Cole et al., 1999, 
2000; Farook et al., 2007). An arm visit was defined as all four paws in one arm. 
Behavior was recorded using a tripod-mounted video recorder (SONY). An experimenter 
remained in the room but was screened from the animals’ view.  
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Analysis 
 For each dependent variable a 2 x 2 ANOVA (ETOH Exposure x Treatment) was 
conducted. Post hoc tests (Fisher’s protected t) were conducted to further explore 
significant effects. 
 
Results 
 JR-220 reduced stretched-attend posture in ETOH and saline-treated animals. A 2 
x 2 ANOVA for stretched-attend behaviors revealed main effects of both pretreatment 
and JR treatment. Pretreatment with ETOH was associated with increased stretched-
attends, F(1,20)=33.665 p=.029, while JR treatment was associated with reductions in the 
behavior, F(1,20)=29.106 p=.002. Post hocs revealed that among JR-naïve animals, 
ETOH pre-exposure was associated with increases in stretched-attends, relative to saline 
(p=.001). JR-associated reductions were evident among both saline (p<.001) and ETOH-
pretreated controls (p<.001).  These differences are depicted in Figure 16. 
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Figure 16. Stretched-Attend Behaviors 
 
 JR-220 was associated with increases in closed-arm occupancy and reduction in 
open-arm occupancy. A 2 x 2 ANOVA conducted for time spent in closed arms detected 
a main effect of JR, such groups receiving JR spent greater time in the closed arms of the 
maze, F(1,20)=7.425 p=.014. Post hoc tests revealed that the significance of this effect 
persisted for saline pretreated animals (p=.016), but was not significant for the ETOH-
pretreated animals. Identical analyses were conducted for time spent in open arms; a 
significant main effect of JR, such that JR treatment reduced time spent in open arms, 
was detected, F(1,20)=10.282 p=.005. Again, this effect was significant among saline-
pretreated animals, but not ETOH animals. These results are depicted in Figure 17, with 
the scales being made equal to facilitate direct comparison between the variables. 
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Figure 17. Time Spent in Closed vs. Open arms 
 
 
 
 JR-220 was associated with hypoactivivity in saline-treated animals. A 2 x 2 
ANOVA for total arm entries revealed main effects for both pretreatment and JR 
treatment. Pretreatment with ETOH was associated with increased arm entries in the 
maze, F(1,20)=5.672 p=.029, while JR treatment was associated with reductions in 
entries, F(1,20)=13.859 p=.002. Post hocs revealed that JR-associated reductions in 
activity persisted only among saline-treated animals (p=.004), although the reduction 
approached significance among ETOH-treated animals (p=.07). These results are 
depicted in Figure 18.  
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Figure 18. Total Arm Entries 
 
 
EPM Summary 
 The primary measure of interest in the cue-conditioned EPM screen was 
stretched-attend postures, thought to index conditioned withdrawal behavior. ETOH-
exposed animals produced a greater number of stretched-attends in the conditioned 
environment, relative to controls. Stretched-attends in this group were significantly 
reduced following a 20 mg/kg dose of JR-220. While this action is consistent with our 
hypothesis, JR’s action in ETOH-naïve animals provided some interpretational difficulty; 
JR reduced stretched-attends significantly, and with a similar magnitude as was noted for 
ETOH-exposed animals. 
 
One possible interpretation would indicate a generalized anxiolytic effect. 
Agmatine (of which JR-220 is an analogue), as well as a number of compounds which 
would be hypothesized to produce agmatine-like action (including L-arginine, DFMO, 
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aminoguanidine and arcaine) are known to reduce ETOH-associated withdrawal anxiety 
in the EPM (Taksande et al., 2010), consistent with the hypothesis of a generalized 
anxiolytic effect. However this anxiolytic action would be atypical, as open-arm dwell-
time was reduced by JR (and closed-arm dwell-time increased) among the ETOH-naïve 
group. Generally, this closed-arm preference would be interpreted as evidence of an 
anxiogenic action.  
 
It is also possible that reduction in stretched-attends was due to a generalized 
hypoactivity induced by JR, an interpretation consistent with the noted reduction in arm 
entries among ETOH-naïve animals and the trend (p=.07) toward a reduction in ETOH-
exposed animals. This interpretation is also supported by the effects of the 40 mg/kg JR 
dose in this paradigm (data not shown). The 40 mg/kg dose resulted in complete 
immobility in a subset of animals, precluding any interpretation of stretched-attend 
behaviors, and thus this data was discarded. 
 
While JR’s effects in this screen were equivocal, reductions in stretched-attend 
behavior among ETOH-exposed animals at least suggested the potential to reduce 
ETOH-associated cues. Thus, when considered in light of its efficacy in previous 
experiments, JR was advanced to the more complex behavioral screens. However, we 
decided that analyzing JR’s effects on activity in a more direct manner would be prudent 
(activity data are presented below in Experiment 7). 
Although results are consistent with the hypothesis that JR would reduce stretched-
attends, however they add little additional support, considering noted interpretational 
issues. 
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Experiment 4: Alcohol Deprivation Effect 
 The alcohol deprivation effect (ADE) refers to temporary increases in ETOH 
consumption, compared with baseline conditions, when ETOH is reinstated following a 
period of forced abstinence (Sinclair & Senter, 1967). The ADE is thought to indicate 
relapse-like behavior (Spanagel et al., 1996). The phenomenon is noted across several 
species, including rats (e.g., Vengeliene, 2003), mice (e.g., Salimov et al., 1993), non-
human primates (e.g., Kornet et al., 1990) and humans (Burish et al., 1981; Mello & 
Mendelson, 1972). Adding to its face validity to human relapse, the ADE phenomenon is 
noted to occur following short deprivations (e.g., 12 h; Sinclair & Li, 1989) as well as 
following an extended abstinence period (75 d; Sinclair et al., 1973). 
 
 Interestingly, alcohol preference among rodents appears relatively unrelated to 
their propensity to display an ADE (for review see Rodd et al., 2004). While the alcohol-
preferring (“P”) rats display robust ADE behaviors, the Alko Alcohol (“AA” line) rats 
only display short term (12 and 24 h) ADEs (Sinclair & Li, 1989); Sardinian alcohol-
preferring (“sP” line) rats do not display ADE behavior (Agabio et al., 2000); and high 
alcohol drinking (“HAD” line) rats display ADE only under certain conditions (Rodd-
Henricks et al., 2000). Vengeliene and colleagues examined these preferring lines with 
Wistar rats (2003) and found ADE behavior only in the P and Wistar animals. However, 
the majority of this work examines ADE following only the first deprivation period. 
When repeated deprivation periods are used, ADE behaviors in preferring lines (e.g., 
HAD rats) which are not immediately evident initially, can emerge (Rodd-Hendricks et 
al., 2000). Similarly, in animals which do display initial ADE behaviors, repeated 
deprivation cycles can markedly increase intake; one study demonstrated 16 g/kg 
consumption during the 24 hr following reinstatement in P-rats (Li et al., 1993). 
 
 Taken together, these findings suggest that relapse-like behavior thought to be 
modeled in the ADE paradigm may reflect pathophysiological changes occurring during 
chronic consumption and abstinence, rather than the positive reinforcing value of ETOH 
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or initial ETOH preference. However, the noted ability of naltrexone to reduce ADE 
behavior (Heyser, Moc & Koob, 2003; McBride, Le & Noronha, 2002) suggests that the 
behavior is still under at least partial control of the positively reinforcing value of ETOH 
following reinstatement. While the mGLUr antagonist, MPEP, reduces ADE behavior 
(Backstrom et al., 2004), the efficacy of acamprosate in this paradigm (Vengeliene et al., 
2010; McBride, Le & Noronha, 2002) is of greatest relevance to the current work, and 
suggests the predictive validity of our ADE procedure. 
 
 Although described in detail below, our modified ADE screen uses Sprague-
Dawley rats, which do not readily acquire significant ETOH self-administration. Thus, 
we employ a sucrose-fading procedure to train drinking. Animals undergo at least three 
reinstatement periods after deprivation. The first is an untreated period to verify that the 
deprivation effect is detectable. The second and third reinstatements are conducted 
following treatment with either the compound of interest, or vehicle, in a within-subject 
manner (with treatment order balanced across groups). This procedure allows us to 
efficiently and reliably produce ADE behavior in Sprague-Dawleys following less than 
one month of ETOH exposure. 
Specifically, we hypothesized JR-220 would attenuate increases in consumption following 
ETOH reinstatement, relative to baseline levels. 
 
Subjects 
 Subjects were male Sprague-Dawley rats individually housed in plastic cages in a 
temperature-controlled colony room (70°±2 F) on a 12h light-dark cycle, with food and 
water provided ad libitum. 
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ADE Procedure 
 Male Sprague-Dawley rats were trained to consume ETOH using a sucrose-fading 
procedure, which entailed gradually replacing the sucrose in a 10% solution with ETOH, 
until animals were consuming a sucrose-free 12% ETOH solution. Free access to water 
was maintained throughout the experiment in one drinking tube, while varying solutions 
of sucrose and ETOH were provided in the other. The sucrose fading schedule is 
presented in Table 5. 
 
Table 5. Sucrose Fading Schedule 
 
 
 
 
 
 
 
 
 Ethanol consumption during the last 3 days of 12% ETOH access was averaged 
and used as a baseline for comparison with post-deprivation consumption. Following the 
sucrose-fading procedure, ETOH deprivation/reinstatement cycles began. Each 
reinstatement period lasted for 72 hours. Deprivation periods were varied at 4±1 days, to 
insure that the animals did not adapt to a schedule. All animals received a single (non-
drug treated) reinstatement cycle to assess elevations in drinking compared to baseline. 
During the following reinstatement period animals were randomly divided into treatment 
groups, receiving either drug or saline. Two experiments were conducted (each 
examining a different dose of JR); separate animals were used for each. An initial 
Phase  Solution  
Days 1-3  Water in both bottles  
Days 4-6 One bottle replaced with 10% sucrose  
Days 7-9 10% sucrose / 3% ETOH  
Days 10-12  10% sucrose / 6% ETOH  
Days 13-15  10% sucrose / 9% ETOH  
Days 16-18  10% sucrose / 12% ETOH  
Days  19-21  5% sucrose / 12% ETOH  
Days  22-27  12% ETOH  
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experiment examined a 20 mg/kg dose (n=54), followed by a smaller-scale experiment 
examining 10 mg/kg (n=13) designed to alleviate interpretational issues concerning 
general fluid consumption. Injections were administered (i.p.) 30 minutes prior to ETOH 
reinstatement, and then repeated daily for the duration of the treatment phase. The 
dependent measure was ETOH consumption (g/kg BW). 
 
Analysis 
 Paired-samples t-tests were used to compare g/kg ETOH consumption during 
each day of the ADE phase with baseline drinking. Total fluid consumption was also 
analyzed in this manner. Paired-samples t-tests were further utilized to disambiguate the 
direct effects of JR, as compared to saline, on water consumption. 
 
Results 
20 mg/kg JR 
 20 mg/kg JR appeared to both attenuate ADE behavior, and reduce consumption 
on days 2 and 3. Paired sample t-tests revealed that following a deprivation period, the 
animals consumed significantly more ETOH following reinstatement, compared to their 
baseline drinking.  A similar pattern as described above was observed, with increased 
consumption on day 1, t(53)=3.890, p<.001, and day 2, t(53)=3.087, p=.003. Following 
treatment with JR-220, day 1 consumption did not differ from baseline, however 
consumption was reduced on day 2, t(53)=2.693, p=.010, and day 3, t(53)=4.164, p>.001. 
Animals which received saline consumed significantly more on day 1, t(53)=5.170, 
p>.001 and 2, t(53)=2.643, p=.011, relative to baseline. ADE phases compared with 
baseline drinking are depicted in Figure 19. 
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Figure 19. 20 mg/kg JR in ADE 
 
 
 No differences in water consumption were associated with the untreated 
reinstatement phase, however both JR-220 and saline injections were associated with 
reductions in water consumption during all injection days. In order to examine whether 
JR-220 was associated with reductions in water consumption compared to saline controls, 
a secondary set of paired-samples t-test was employed to compare these groups. Water 
consumption was reduced by JR during day 1 t(53)=3.673, p=.001, and day 2, 
t(53)=2.423, p=.019, but not day 3 of reinstatement. These results are depicted in Figure 
20.  
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Figure 20. Water Consumption in ADE Reinstatement Phases (20 mg/kg).  
 
 
10 mg/kg JR 
 10 mg/kg JR appeared to attenuate ADE behavior. Paired samples t-tests revealed 
that following a deprivation period, the animals consumed significantly more ETOH 
following reinstatement, compared to their baseline drinking. This increase persisted for 
both day 1, t(12)=3.084, p=.006, and day 2, t(12)=2.397, p=.034. Animals which received 
saline consumed significantly more on day 1 of the drinking phase, t(12)=3.841, p=.002.  
During the treated ADE phases, 10 mg/kg JR treatment appeared to attenuate increases in 
consumption. ADE phases compared with baseline drinking are depicted in Figure 21. 
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Figure 21. 10 mg/kg JR-220 in ADE 
 
 
 A second set of t-tests were performed to examine the effects of JR on water 
consumption during reinstatement. No differences in water consumption were associated 
with the untreated reinstatement phase, or treatment with JR-220. However, water 
consumption on the first day of reinstatement was significantly lower among animals 
administered saline, relative to baseline drinking. These results are depicted in Figure 22. 
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Figure 22. Water Consumption During ADE Reinstatement Phases (10 mg/kg) 
 
 
ADE Summary 
 Using a modified procedure designed to facilitate efficient drug screening, we 
demonstrated that Sprague-Dawley rats with less than a month of exposure to ETOH-
containing solutions will substantially increase ETOH drinking behaviors following a 
period of forced abstinence. This is notable both for the relatively short pre-deprivation 
drinking period, as well as the rat strain used, as Wistar or various selectively bred lines 
are used most commonly in this procedure. Additionally, one advantage of our screening 
procedure is the relatively high levels of consumption it produces, ranging from 6-9 g/kg 
during the first 24h following reinstatement, which contributes to the face validity of the 
screen. Our observed levels of consumption are greater than is generally found in other 
works (with several notable exceptions involving P-rats), however, the inclusion of a 
sucrose fading procedure to accelerate ETOH consummatory behavior also raises the 
possibility that consumption is being partially driven by previous associations with 
sweetness/calorie content. While this complicates interpretation somewhat, it does not 
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necessarily subtract from the face validity of the screen, as initiation of ETOH 
consumption in humans rarely involves high ETOH/low carbohydrate solutions. 
 
 JR-220 administration at both 10 and 20 mg/kg doses attenuated the ADE, 
reducing post-reinstatement consumption to control levels (or below). Paired-samples t-
tests indicated that following the 10 mg/kg dose, consumption levels during all treatment 
days were indistinguishable from control levels, compared to saline treatment, in which a 
significant day 1 increase was noted. Furthermore, the 10 mg/kg dose was not associated 
with any reduction in water consumption. Saline-treated animals displayed reduced water 
consumption during day 1, however this was most likely do to their preference for the 
ETOH solution. 
 
 20 mg/kg administration of JR was also associated with a reduction in ADE 
behavior. Following reinstatement, no increases in ETOH consumption relative to control 
were noted in the first 24 h of access, in contrast to the significant increase in day 1 
consumption among vehicle-treated animals. Interestingly, while animals treated with 10 
mg/kg JR were no different from controls on any of the treatment days, 20 mg/kg JR was 
associated with reductions in drinking on days 2 and 3. However, this is consistent with 
the hypothesis that JR is capable of reducing a number of ETOH-associated behaviors, 
including relapse (ADE day 1 consumption), and general reductions in consumption, 
reflecting reduced reinforcing value. Reductions in water consumption during the treated 
ADE phase were noted. While some reduction is expected due to the hydrating capability 
of the injections (injections contained 2.5-5 mL saline, depending on body weight), direct 
comparison of the saline and JR-220 treatments indicated a significant reduction in water 
consumption associated with JR. Since saline treated animals demonstrated greater 
preference for the ETOH solution, yet still consumed more water than JR-treated animals, 
this is unlikely to be an artifact. The most likely possibilities for this noted reduction in 
water include general reductions in the reinforcing value of natural rewards or a general 
reduction in activity levels (including normal drinking behavior). The former possibility 
85 
 
 
is unlikely, as JR has been directly examined in other drinking paradigms and found not 
to affect water consumption (Justin Rhodes, personal communication). Furthermore, the 
10 mg/kg dose was associated with reductions in ETOH but not water consumption, 
arguing against a generalized reduction in reinforcement. Thus, JR’s potential effects on 
activity remained a concern and were consequently examined in Experiment 7. 
  
 CP was not examined in this screen due in part to limited resources, and in part 
because NR2B antagonism has been examined previously in the ADE paradigm; the 
NR2B antagonist ifenprodil dose dependently reduces ADE behavior (Vengeliene et al., 
2005). Thus, while CP’s efficacy would have been noteworthy due to the noted 
differences in its binding profile, the recognition of NR2B antagonist efficacy in this 
paradigm influenced our decision to prioritize its examination in behavioral paradigms in 
which NR2B involvement is less well-established (i.e., binge drinking). 
Taken together, these results supported the hypothesis that inhibitory polyamine 
modulation has the ability to attenuate reinstatement-associated increases in ETOH 
consumption. Attenuation of relapse behavior in this experiment was encouraging, 
however this paradigm lacks a major component associated with human relapse: stress. 
Thus, we advanced JR to Experiment 5, examining its effects in chronically stressed 
animals. 
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Experiment 5: Stress-Associated Drinking 
 It is well known that stress increases alcohol consumption in a variety of species, 
and is thought to be a primary contributor to relapse behavior in humans. Thus, we 
included a stress-related paradigm into our screening hierarchy. A variety of stressors are 
known to increase drinking behaviors in rodents, including foot-shock (e.g., Matthews et 
al., 2008), social isolation (e.g., Nunez et al., 2002) and restraint/immobilization (e.g., 
Farook et al., 2009). C57BL/6J mice are known to readily consume ETOH, and their 
consumption is both increased following stress challenge (e.g., Boyce-Rustay, 2008) and 
sensitive to such factors as quality, severity, duration and frequency of stress. We 
therefore used this strain in a simple restraint-stress procedure to screen for the ability of 
our compounds to reduce stress-associated consumption. 
 
 Unfortunately, the literature involving GLUergic manipulations of stress-
associated drinking is limited. There is some evidence suggesting acamprosate has the 
ability to reduce stress-associated increases ETOH consumption (Füllgrabe, Vengeliene 
& Spanagel, 2007), however these findings were age and sex-specific. Clinically, 
acamprosate appears anxiolytic (Schwartz et al., 2010), and in a sample of patients 
comorbid for anxiety and alcohol misuse disorders, reduced both anxiety symptoms and 
alcohol use (Schwartz, Chilton & Aneja, 2007). These findings suggest compounds with 
‘acamprosate-like’ action will positively modulate alterations in drinking behavior 
resulting from stress, despite the paucity of available preclinical examinations involving 
NMDAr manipulation. 
 
 While acamprosate has not yet been examined in this restraint-stress procedure, a 
previous study conducted by our group using topiramate (Farook et al., 2009) suggests 
that restraint elevates drinking behavior, and that such elevation may be moderated by the 
‘acamprosate-like’ action of topiramate. While the screen presented below was designed 
in a highly similar manner to that described by Farook (2009), the size of the unrestrained 
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group was substantially reduced in order to increase efficiency and throughput, and only 
saline and a single  dose of JR was examined in controls. 
Specifically, we hypothesized that stress-induced increases in ETOH consumption would 
be attenuated following JR-220 administration. 
 
Subjects 
 Male C57BL/6J (n=28) mice weighing 29±2 g (15-18 weeks old; Jackson 
Laboratory, Bar Harbor, ME) were singly housed in standard polycarbonate cages with 
corncob bedding. Chow and water were provided ad libitum.  
 
Procedure 
 Prior to the start of an experiment, C57BL/6J mice were allowed to adjust to the 
colony room for a period of 7 days, following shipment. Afterwards, water and ETOH 
were available in feeding tubes (Dyets Inc., PA) inserted directly into the animal cage. 
During the course of 7 days, the concentration of ETOH was gradually increased from 
3% (days 1-2) to 6% (day 3-5) to 12% (days 6-7). Drinking tube position was alternated 
daily in order to avoid any positional bias. Water and ETOH consumption were measured 
daily, throughout the experiment. 
 
 At the start of the restraint phase, mice were divided into groups; 20 animals 
received restraint, with 8 controls. Restraint was performed daily, for 5 days, by placing 
mice into transparent plexiglass restraint chambers (10 cm x 4.5 cm x 3.2cm) for one 
hour. Unrestrained animals were handled briefly, then transported in their home cage to 
the restraint room and left for one hour. Restraint was ceased after 5 days (prior to the 
first day or treatment). Animals exposed to the restraint stress were subdivided into four 
groups (n’s=5), each receiving 0, 10, 20 or 30 mg/kg JR-220. Unrestrained animals were 
divided into two groups (n’s=4), receiving saline injections or the high dose (30 mg/kg) 
of JR-220. Injections were repeated, daily, for five days, post-restraint. 
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Statistics  
 An initial repeated measures ANOVA (group x day) was performed between 
unrestrained controls and restrained animals, to assess the effects of daily restraint on 
ETOH consumption. Following restraint, the multiple doses of JR were analyzed using a 
two-way repeated measures ANOVA (Dose x Day). Additional ANOVAs, and 
subsequent post hocs (Fisher’s protected t) were conducted to further examine significant 
effects, where appropriate. 
 
Results  
 Restraint stress was associated with increases in ETOH consumption. A group x 
day RM ANOVA detected a main effect of group, revealing that ETOH consumption was 
increased among animals undergoing restraint, F(1, 26)=122.479, p<.001. Additionally, a 
significant interaction between group and day was noted F(1, 26)=6.773, p=.015. Thus, t-
tests were conducted between groups for each day, individually. In all cases a significant 
difference between groups was detected (p<.001, p=.001, p<.001, p<.001, p<.001, for 
days 1-5, respectively). Graphing the interaction (Figure 23) suggests divergence of 
ETOH consumption over time, in a group-dependent manner. Consumption among 
restrained animals increased over time, while unrestrained animals’ consumption 
decreased over time. 
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Figure 23. Restrained vs. Unrestrained Drinking 
 
 Following the 5-day restraint phase, restrained animals were administered one of 
four doses of JR (0, 10, 20, 30 mg/kg), daily, and allowed to consume ETOH freely for 
an additional 5 days. JR administration reduced drinking in a time-dependent manner. An 
initial RM ANOVA detected an interaction between day and dose, F(12, 64)=2.186, 
p=.023, thus, individual ANOVAs were conducted for each day, individually. No effect 
of dose was noted for days 1 or 2, however by day 3 dose emerged as significant, 
F(3,19)=10.958, p<.001, and remained significant during day 4, F(3,19)=21.722, p<.001, 
and day 5, F(3,1)=8.636, p<.001. Fisher’s post hocs were performed for days 3-5. During 
day 3, saline treated animals consumed significantly more ETOH than 10, 20, or 30 
mg/kg JR-treated animals (p=.008, p<.001, p<.001, respectively). On day 4, saline-
treated animals again consumed significantly more ETOH (p=.006, p<.001, p<.001, 
respectively), however the animals exposed to 30 mg/kg also consumed less than animals 
receiving either 10 or 20 mg/kg JR (p<.001, p=.008, respectively). On day 5 JR-treated 
animals again consumed less than saline-treated (p=.010, p=.003, p<.001, respectively), 
although among JR-treated animals consumption did not differ as a function of dose. 
These results are depicted in Figure 24, below. 
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Figure 24. JR-220 Treatment (Following 5-day Restraint Period) 
 
 Additional analyses were conducted on animals which received no exposure to 
the restraint paradigm, but were treated with either saline or the highest (30 mg/kg) dose 
of JR-220. An RM ANOVA (treatment x day) was conducted, however no main effects 
or interactions were noted.  
  
 Since the investigation of JR in unrestrained animals was not a primary focus of 
this experiment, sample size for this analysis was low (n’s=4). Thus, we were concerned 
that the (treatment x day) RM ANOVA lacked sufficient power to detect differences on 
individual days. We therefore chose to examine the final day of treatment (Day 5), using 
a t-test. 30 mg/kg JR appeared to reduce Day 5 consumption, t(6)=2.900, p=.033, despite 
the lack of an overall (treatment x day) interaction (depicted in Figure 25). While the t 
value for this analysis was modest, the low n’s suggested a sizeable effect. The effect size 
for the 5th day was found to be a “large” effect (Cohen’s d=2.37). 
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Figure 25. Unrestrained Animals, 0 vs. 30 mg/kg JR 
 
 
 
Restraint Stress Summary 
 Prior to drug treatment, daily restraint stress induced elevations in ETOH self-
administration. The primary measure of interest in this screen was alterations in ETOH 
self-administration following chronic stress.  At all three doses examined (10, 20, 30 
mg/kg) JR-220 was capable of reducing consumption. However, the temporal pattern of 
this reduction was particularly interesting; during the first 2 days of JR administration no 
differences were detectable, and it was only during the 3rd, 4th and 5th days of ETOH 
consumption that such differences emerged. However, this is not a unique pattern.  
Previous use of this procedure (Farook et al., 2009) produced a similar pattern of results, 
with significant differences between treated and un-treated groups not emerging until the 
last half of the treatment phase. One interpretation of such delayed efficacy would 
suggest that both compounds require several days for concentrations to reach maximally 
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effective levels. While the 21 h half-life of topiramate (Bialer, 1993) is consistent with 
this interpretation, no data is currently available concerning metabolism of JR-220. An 
alternative interpretation is that dysregulation of HPA function and resultant negative 
affect are not immediately reversible, but rather need some time to ‘balance’ or ‘down-
regulate’. 
 
  However, while patterns of slow-onset efficacy in restrained animals are similar 
between studies, the patterns of ETOH consumption during the restraint phase, and the 
magnitudes of consumption in both restrained and non-restrained animals appear 
markedly different when the current project is contrasted with the topiramate study. 
Consumption among restrained vs. unrestrained animals in the topiramate study increased 
from ~10 to ~19 g/kg and ~7.5 to ~12.5 g/kg in restrained and unrestrained animals, 
respectively; the current study observed only a slight increase associated with restraint 
(~9 to ~11.5 g/kg), and a decrease (~6 to ~4 k/kg) in unrestrained animals. Since both 
sets of experiments employed nearly identical methodologies, such differences are 
puzzling. However, the overall findings from both studies, that restraint-associated 
increases in consumption may be attenuated in a time-dependent manner via GLUergic 
modulation, are consistent. 
 
 The inclusion of unrestrained controls in this paradigm was primarily to insure 
that restraint stress resulted in increased consumption, however following the restraint 
phase this group allowed for the additional examination of JR in unrestrained animals. A 
JR-associated reduction was noted, however only after several days of treatment (similar 
to the restrained animals). Finally, the large effect size of the Day 5 difference suggests 
the reliability of this finding, even with unfortunately low n’s.  
These results were consistent with our hypothesis that inhibitory polyamine modulation 
would reduce stress-associated ETOH consumption.  
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Experiment 6: Drinking in the Dark (Screen) 
 As noted previously, the C57BL/6J mouse is considered an alcohol-preferring 
strain. However, among C57s, other mouse strains, or other species, it has been 
(historically) difficult to produce binge-like self-administration to the point of behavioral 
intoxication. For instance, while C57s will take nearly all daily fluid intake from a 10% 
ETOH solution in a 2-bottle choice, 24 h access paradigm, measurable effects on 
physiology and/or behavior are lacking and pharmacologically significant BEC levels are 
not maintained (Dole & Gentry, 1984). Although some noted exceptions exist (e.g., 
Middaugh et al., 1999; Ryabinin et al., 2003), these and other binge models generally 
involve extended periods of previous administration, stress (or other environmental 
manipulation, e.g., food deprivation) or previous forced administration (e.g. ETOH vapor 
inhalation chambers). While operant techniques are able to avoid many of these pitfalls 
(e.g., Roberts, Heyser & Koob, 1999), the procedures require significant individualized 
training over time, and are thus ill-suited for high-throughput screening.  
 
 Fortunately, a limited-access procedure which involves neither food nor water 
restriction, and leads to pharmacologically significant levels of consumption, has recently 
been established. Rhodes and colleagues (2005), in a methodologically rigorous 
examination, described the tendency of C57BL/6J mice to consume significant quantities 
of alcohol under limited-access conditions (2-4 hours) during their active (dark) cycle, 
termed ‘Drinking in the Dark’. Under these conditions the mice are known to consume 
high concentrations (20%) of ETOH to the point of intoxication with BECs as high as .16 
g/dl (Rhodes et al., 2005). Furthermore, several behavioral indices of intoxication are 
noted, including impaired performance on the accelerating rotarod and balance beam tests 
(Rhodes et al., 2007) and gait abnormalities (Rhodes et al., 2005). Finally, the 
establishment of such high levels of consumption requires few days of ETOH experience, 
and may be generated within 1-2 weeks. This DID procedure thus provides a simple 
binge model with high face validity which is particularly well suited to genetic and 
pharmacological investigations. 
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 The predictive validity of this model has been established using a number of 
compounds. The binge-like nature of DID behavior and the short amount of time required 
to establish it, suggest that in this particular model consumption may be driven largely by 
positive reinforcement. The effects of VTA micro-injection of baclofen (Moore & 
Boehm, 2009), as well as systemically administered naltrexone (Kamdar et al., 2007), are 
consistent with this hypothesis. However, GLUergic manipulations also appear to reduce 
consumption; both MPEP (an mGLUr inhibitor) and acamprosate significantly and dose-
dependently reduce the behavior (Gupta et al., 2008). Interpretation of such efficacy is 
equivocal; these GLUergic compounds may serve to reduce positive reinforcement, or, 
despite short onset of the binge-like behavior, it may still be partially driven by the 
negatively reinforcing value of ETOH. 
 
The experiments presented below are DID screens which were adapted from 
Rhodes and colleagues (2005). While the basic methodology was retained, treatment 
schedules differed (allowing us to assess prolonged effects of treatment on ETOH 
consumption the day following treatment) and dose ranges were more limited (to 
facilitate higher throughput). Unlike many of the aforementioned screens, this procedure 
was novel for our lab at the time of JR and CP testing, thus we included acamprosate in 
these initial experiments to further the establishment of the screen’s predictive validity. 
 
We hypothesized that the high levels of ETOH consumption noted during brief periods of 
dark-cycle access to ETOH would be reduced by inhibitory polyamine modulation via JR 
and CP. 
 
DID  (Screen) Subjects 
 Male C57BL/6J (N=20) mice weighing 30±3 g (15-18 weeks old; Jackson 
Laboratory, Bar Harbor, ME) were singly housed, in a room maintained on a 12:12 
reversed light/dark cycle, with lights turned off at 0600 h and on at 1800 h EST. Red 
incandescent lamps were used during feeding, cage-changing and testing to avoid 
circadian disruption. Animals were housed in standard polycarbonate cages with corncob 
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bedding. Rat chow and water were provided ad libitum, except when ETOH was 
substituted for water.  
 
DID (Screen) Procedure  
 Upon arrival, animals were habituated to the colony room for seven days. Twenty 
percent ETOH solutions were prepared daily. ETOH solutions were delivered in 10 ml 
graduated cylinders, fitted with double ball bearing sipper tubes (to prevent leakage). 
ETOH access was initiated 4 hr into the dark cycle. This was done in the home cage, 
where animals were singly housed. The cylinders remained in place for 4 hrs, after which 
cylinders were removed and water bottles re-introduced.  
 
 A three week (5 days/week) period ETOH exposure was conducted prior to drug 
treatment. Each animal received all compounds tested, in a counterbalanced, latin-square 
design (Figure 26). ETOH consumption was allowed each day preceding and following a 
treatment.  Screen 1 examined saline, 10 mg/kg JR and 10 mg/kg CP. Screen 2 examined 
saline, 300 mg/kg acamprosate, and 20 mg/kg JR. Doses were selected based on efficacy 
in previous experiments and/or selected from the literature. Figures 27 and 28 depict the 
treatment schedule and consumption prior to treatment exposure, respectively. 
 
Figure 26. Latin-Square Design for Screen 1 and Screen 2 
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Figure 27. DID ETOH Access Schedule (Single Phase; Dark/Light Boxes Indicate 
ETOH/Water, Respectively) 
 
 
Figure 28. Daily DID Consumption (4 hr/day) Prior to Treatment Phase 
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DID (Screen) Results 
 Data were analyzed with paired-samples t-tests, comparing treatment groups to 
controls. An alpha of .05 was used for both phases of the experiment. In screen 1, ETOH 
consumption was significantly reduced following CP treatment, compared to saline, 
t(19)=3.483, p=.002. Likewise, JR-220 treatment significantly reduced consumption, 
t(19)=4.041, p=.001. These results are presented in Figure 29. 
 
Figure 29. CP-101,606 (10 mg/kg) and JR-220 (10 mg/kg) in DID 
 
 
 In screen 2, 20 mg/kg JR reduced ETOH consumption relative to saline 
t(18)=9.074, p<.001. Acamprosate was associated with increased consumption, 
t(18)=2.161, p=.044 (an unexpected finding, discussed in detail below). These results are 
presented in Figure 30. 
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Figure 30. JR-220 (20 mg/kg) and Acamprosate (300 mg/kg) in DID 
 
 
 
DID (Screen) Summary 
 Results from both DID experiments indicated the abilities of CP and JR to reduce 
binge-like consumption in this limited-access drinking paradigm. In the first experimental 
screen, due to concerns about potential secondary effects of JR-220 (i.e., sedation), we 
selected the lowest dose (10 mg/kg) of JR which demonstrated efficacy in previous 
drinking screens. Due to the lack of data concerning CP-101 in ETOH consumption 
paradigms, we selected a moderate dose (10 mg/kg) based on other animal studies which 
demonstrated positive behavior effects (e.g., Kundrotiene et al., 2004).  Both compounds 
reduced consumption by a magnitude of ~50%. In the subsequent screen, a higher dose of 
JR was selected in order to establish (or at least begin to provide evidence for) a dose-
dependent effect. While such an effect would have been interesting to examine for CP-
101 as well, we prioritized the examination of acamprosate in order to demonstrate the 
predictive validity of the screen under our particular experimental methods. The higher 
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dose of JR (20 mg/kg) reduced consumption by an even greater proportion, relative to 
saline-treated animals.  
 
 Acamprosate was unexpectedly associated with increases in consumption. Exactly 
what this indicates is unclear, however it should be noted that consumption following 
saline injection during screen 2 was unusually low (~2.25 g/kg) compared with screen 1 
(~3.25 g/kg), and may have either driven or contributed to this effect. Vehicle-associated 
consumption in the DID literature resembles our screen 1 results, suggesting untreated 
consumption in screen 2 was abnormally low. The nature of our screening procedure is 
such that to maximize the number of compounds examined, lower subject sizes than 
might otherwise be expected in more rigorous experiments, are utilized. Thus, although 
not explicitly noted above, our post hoc analyses and treatment of family-wise error 
throughout this project are generally liberal. While advantageous in some respects, this 
increases the probability of type 1 errors. Considering this liberality, the low magnitude 
of the observed effect (~.5 g/kg), the abnormality of screen 2 vehicle-associated 
consumption and the inconsistency with Dr. Rhodes’ examinations of acamprosate in a 
similar model, we felt drawing conclusion from this result would be premature. 
 
 While acamprosate effects in our DID screen should be investigated further, 
results from Experiments 1-5 suggested that more rigorous exploration using 
standardized models with larger n’s was warranted. While any numbers of well-used 
models in the preclinical literature might have been selected from, DID was attractive for 
two major reasons. Firstly, relative to relapse and cue-conditioning models, NMDAr 
antagonism has remained  largely unexplored in models of binge-like consumption, thus 
DID allowed for both a pointed examination of the potential of these two compounds, as 
well as an opportunity to contribute to an emerging literature. Secondly, while screening 
results from JR and CP appeared quite promising, it was concerning that in our hands 
acamprosate was ineffective; DID remained the only paradigm in which JR/CP results 
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were inconsistent with acamprosate results, which seemed to warrant further 
investigation. Both compounds were tested in the standard DID model (Experiment 8). 
These results supported the hypothesis that inhibitory polyamine modulation would 
reduce binge-like consumption in a limited access DID screen. 
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Experiment 7: Open Field Activity 
 While the positive activity of both JR and CP in the screens presented here is 
encouraging, one interpretational concern involved the effects of these compounds on 
general activity levels. Additionally, the hypoactive effect of JR noted in the EPM, as 
well as the general reduction in fluid consumption noted in ADE, raised suspicion that JR 
may be altering activity. For these reasons alone, examining activity seemed prudent, 
however the examination of these compounds also afforded their comparison to other 
GLUergic manipulations, as well as secondary analyses of center-zone activity; entries 
into the center are generally associated with reductions in anxiety and are negatively 
correlated with behavioral and physiological measures of fear (Archer, 1973), however 
may also evidence deficits in inhibitory control. 
 
 Open field results are presented by species, using the same order in which the 
behavioral experiments are presented, including Swiss Webster mice (Experiments 2 & 
3), Sprague-Dawley rats (Experiment 4) and C57BL/6J mice (Experiments 5 & 6). All 
open field subjects were drug-naïve (i.e., not used in any previous experiments). 
 
Analysis 
 While methods varied depending on species/strain, activity was analyzed 
similarly, using RM ANOVAs (time x treatment), with either Fisher’s protected t or 
Dunnett’s post hoc tests, as appropriate. Center-dwell time was analyzed with one-way 
ANOVA (treatment), with Fisher’s protected t tests where appropriate. 
 
Open Field Methods (Swiss Webster) 
 The activity of adult male Swiss Webster mice (30±2 g; N=20; n’s=4) was 
analyzed following the administration of both CP and JR. The apparatus was a square, 
black, plexiglass chamber (64 x 64 x 64 cm). Subjects were transported to a darkened 
102 
 
 
testing room and habituated for 10 min. Each subject was then individually placed in the 
open field and recorded for 10 min using a tripod-mounted video recorder (SONY). For 
analysis, the open field was divided into quadrants, each comprising 25% of the total 
area. Additionally, a smaller square (25% of the total area) was super-imposed over the 
center of the open field. The dependent variables included number of quadrant crosses 
and time spent in the center zone. 
 
Results (Swiss Webster) 
 High-dose CP (20 mg/kg) was associated with hyperactivity, while high-dose JR-
220 induced hypoactivity. The initial RM ANOVA (time x treatment) indicated main 
effects of both time F(4,60)=29.622, p<.001, and treatment, F(4,15)=10.562, p<.001. To 
further examine the treatment effect, a one-way ANOVA was conducted using total 
quadrant crosses over the 10-minute activity period. Again, a significant effect of 
treatment was noted, F(4,19)=10.692, p<.001, with Dunnett’s tests indicating significant 
increases in crosses associated with 20 mg/kg CP (p=.054) and decreases associated with 
40 mg/kg JR (p=.007). These results are depicted across time (by block) in Figure 31a, as 
well as summed, in Figure 31b. 
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Figure 31a. Open Field Quadrant Crosses (By Block) Following Saline, JR and CP 
 
 
 
Figure 31b. Open Field Quadrant Crosses (Total) Following Saline, JR and CP 
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 Finally, time spent in the 25% center zone was analyzed using a one-way 
ANOVA (treatment). A significant effect of treatment was noted F(4,19)=5.594, p=.006. 
Dunnett’s tests indicated this effect was driven by increased center dwell-time of 20 
mg/kg CP-treated animals (p=.032). Time spent in the center zone is depicted in Figure 
32, below. 
 
Figure 32. Open Field Center Dwell-Time Following Saline, JR and CP 
 
Open Field Methods (Sprague-Dawley) 
 The activity of (PND45) male Sprague-Dawley rats (N=18) was analyzed 
following administration of JR-220. The apparatus was a circular chamber (36 cm height; 
58 cm diameter) designed to prevent thigmotaxis or excessive time in corners. Subjects 
were injected with IP Saline, 10 or 20 mg/kg JR 30 min prior to activity testing. 10 min 
prior to testing, subjects were habituated to the darkened test room. Each subject was then 
individually placed in the open field and recorded for 30 min using a video tracking 
system (SMART program; Panlab, S.L.). Due to anecdotal observation that acute 
sedative effects of JR were transient, an additional 30 min session was performed, 
beginning 3 hours following the completion of the first session (4-4.5 hr following JR 
injection). For analysis, the open field was divided into center and outer zones, 
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comprising 25% and 75% of the total area, respectively. The dependent variables 
included distance traveled (in 5 min blocks) and the ratio of activity in the center vs. total 
area of the field.  
 
Results (Sprague-Dawley)   
 20 mg/kg JR was associated with reductions in activity. An initial RM ANOVA 
for the first 30-min activity session indicated an interaction of treatment and time, 
F(2,15)=4.252, p=.034, as well as a main effect of JR treatment, F(2,15)=4.055, p=.039, 
thus individual one-way ANOVAs (treatment) were performed for each 5 min block. 
Significant effects of treatment were noted during block 1, F(2,17)=4.731, p=.026; 3 
F(2,17)=4.669 p=.027; and 4 F(2,17)=6.128, p=.003. During block 1 Fisher’s protected t 
post hoc tests indicated a significant reduction in activity associated with 20 mg/kg JR 
treatment, relative to saline (p=.008). During block 3, the 20 mg/kg dose reduced activity 
relative to saline (p=.011) as well as the 10 mg/kg treatment (p=.038). Finally, during 
block 4 the 20 mg/kg dose reduced activity relative to saline treatment, only (p=.003). 
These results are depicted in Figure 33. ANOVA performed for center activity failed to 
reveal any significant effect of treatment. 
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Figure 33. Activity 30-60 min Following JR-220 Administration(Sprague Dawleys) 
 
 At four hours post-injection, activity reductions in 20 mg/kg JR-treated animals 
remained apparent. An initial RM ANOVA for the second 30-min activity session 
indicated an interaction of treatment and time, F(2,15)=9.112, p=.003, as well as a main 
effect of JR treatment, F(2,15)=3.748, p=.048, thus individual one-way ANOVAs 
(treatment) were performed for each 5 min block. Significant effects of treatment were 
noted during blocks 1 [F(2,17)=10.650, p=.001], and 2 [F(2,17)=5.129, p=.019]. During 
block 1 post hoc tests indicated the 20 mg/kg dose reduced activity relative to saline 
(p=.001) as well as the 10 mg/kg treatment (p=.001). During block 2 significant activity 
reductions were again noted for 20 mg/kg JR-treated animals, relative to both saline 
(p=.039) and 10 mg/kg (p=.007) treatment. These results are depicted in Figure 34. 
ANOVA performed for center activity failed to reveal any significant effect of treatment. 
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Figure 34. Activity 4-4.5 hr Following JR-220 Administration (Sprague Dawleys) 
 
 
Open Field Methods (C57BL/6J) 
 The activity of male C57 mice (30±2 g) was analyzed following the 
administration of both CP and JR. Nineteen male C57 mice (30±2 grams) were 
administered 0, 5, 10 or 20 mg/kg CP-101,606 (n’s=4-5/group). In a separate experiment, 
24 additional C57s were administered 0, 10, 20 or 30 mg/kg JR-220 (n’s=6/group). 
Otherwise, methods were exactly as described for Swiss Webster testing, above. 
 
Results (C57BL/6J) 
 An RM ANOVA (time x treatment) conducted on CP-treated animals yielded 
neither a main effect of, nor interaction with, treatment. As conducted previously, a one-
way ANOVA (treatment) using total quadrant crosses similarly failed to detect any effect 
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of CP treatment. Quadrant crossings by block are depicted in Figure 35, below. No 
difference in center dwell-time was detected between treatment conditions. 
 
Figure 35. Open Field Quadrant Crosses Following Saline or CP(C57 Mice) 
 
 The highest dose of JR (30 mg/kg) was associated with marked reductions in 
activity. A RM ANOVA (time x treatment) conducted on JR-treated animals indicated 
both a time by treatment interaction, F(12,80)=3.700, p<.001, and a main effect of 
treatment F(3,20)=23.635, p<.001. To further examine these effects, one-way ANOVAs 
(treatment) were conducted for each block, individually. Significant treatment effects for 
block 1, F(3,23)=12.852, p<.001, block 2, F(3,23)=15.292, p<.001 and block 3, 
F(3,23)=60.056, p<.001 were noted, such that 30 mg/kg JR reduced activity relative to all 
other groups (all p’s<.001). The same effect was noted for block 4, F(3,23)=4.159, 
p=.019, wherein 30 mg/kg reduced activity compared to saline (p=.015), 10 (p=.006) and 
20 mg/kg (p=.010), and block 5 F(3,23)=8.516, p=.001, wherein 30 mg/kg reduced 
activity compared to saline (p<.001), 10 (p=.009) and 20 mg/kg JR (p=.001). 
Additionally, a one-way ANOVA (treatment) was conducted using total quadrant crosses 
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as the dependent variable. Again, a significant effect of treatment was detected, 
F(3,23)=23.748, p<.001, such that 30 mg/kg JR-treated animals were hypoactive 
compared to all others (all p’s<.001). These results are depicted across time in Figure 36, 
and summed in Figure 37, below. No difference in center dwell-time was detected 
between treatment conditions. 
 
Figure 36. Open Field Quadrant Crosses Following Saline or JR (C57 Mice)
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Figure 37. Open Field Quadrant Crosses (Total) Following Saline, 10, 20 or 30 mg/kg 
JR (C57 Mice) 
 
 
Open Field Summary 
 This final experiment was somewhat atypical compared with those preceding it; 
while it can be considered a screen, its main purpose was to facilitate interpretation of 
experiments 1-6. Taken together, the activity data presented above indicate that while JR 
and CP are both capable of behavioral disruption at higher doses (including doses 
analyzed in previous experiments), several lower doses which tested positively 
throughout the screening procedure showed no evidence of such disruption.  
 
 The first open field analysis included Swiss Webster mice, and was designed to 
analyze the highest and lowest doses of JR and CP which demonstrated efficacy in the 
behavioral experiments (10 and 40 mg/kg and 1 and 20 mg/kg doses, respectively). 
Importantly, at doses which significantly reduced seizure behaviors, CP and JR-treated 
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animals were indistinguishable from controls. However, an interesting difference 
emerged at the high doses. 40 mg/kg JR was associated with an approximate decrease in 
activity of 60%, while 20 mg/kg CP was associated with an approximately 40% increase. 
  
 The second open field analysis included Sprague-Dawley rats, and analyzed only 
JR-220, and examined doses used in the ADE experiment. Anecdotally, JR appeared to 
induce transient sedation in our Sprague-Dawley rats, however observable in-cage 
evidence of sedation disappeared quickly. Therefore in addition to analyzing initial (and 
possibly transient) alterations in activity, 30 min following administration, we re-tested 
the animals 4.5 h following administration. Results were remarkably similar across 
testing periods. The 10 mg/kg dose produced activity which was indistinguishable from 
controls; while the 20 mg/kg dose appeared to reduce activity at both time points, 
producing nearly identical patterns/magnitudes of activity. While activity was certainly 
reduced among 20 mg/kg animals, it should be noted that animals remained active 
throughout both 30 min testing periods, traveling similar distances as the 10 mg/kg and 
saline groups during the last 10 min of the initial test and last 20 min of the final test, 
suggesting the sedation was mild. Importantly, the 10 mg/kg dose reduced relapse-like 
behavior, was not associated with reductions in water consumption and did not induce 
hypoactive behaviors, either initially or several hours post-injection. 
 
 The final open field analysis included C57 mice, and the full range of JR doses 
examined in the restraint stress and DID experiments: 10, 20 and 30 mg/kg doses. 
Additionally, CP was analyzed in 5, 10 and 20 mg/kg doses. While only the 10 mg/kg 
dose was analyzed in experiment 6, this dose ranged was analyzed in anticipation of a 
more thorough DID analysis (described below). While activity among saline and CP-
treated animals was statistically indistinguishable, the lack of an effect was likely due to 
high variance and relatively low power.  The trend toward higher activity among animals 
receiving 10 and/or 20 mg/kg doses was consistent with the observed increase in activity 
displayed by Swiss Webster mice. At the two lower JR doses examined (10 and 20 
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mg/kg), no evidence of activity disturbance was observed, however the 30 mg/kg dose 
was associated with a substantial reduction in activity. Unlike activity data generated in 
rats, the observed activity deficit persisted across all blocks. 
 
 While the additional examination of potential anxiolytic actions of these drugs 
was an advantage of including an open-field assessment, alterations in center-zone 
activity were only evident in the Swiss Webster mice, and the pattern of center-zone 
activity was nearly identical to the general pattern of activity, likely suggesting that 
periods of immobility in these animals largely occurred in the more protected periphery. 
While it is possible that center-zone patterns reflected actions on anxiety-related 
behaviors, the interpretation would include anxiogenic actions of JR-220, which is 
inconsistent with the examinations of compounds thought to have similar mechanisms of 
action (including CP-101).  
Taken together these results suggest that neither JR nor CP disrupt activity at lower 
doses, but each is associated with disruption at higher doses, albeit in opposing 
directions.  
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Experiment 8: Drinking in the Dark (Model) 
 The medications development project, of which this dissertation represents only a 
fraction, was specifically designed for the screening of novel compounds, with the 
intention that “hits” would be subjected to a further testing with more established models, 
using more rigorous methodology, more appropriate controls and/or greater n’s. 
Experiment 8 was designed and included in this dissertation as the first, albeit modest, 
step toward such testing. The DID model was specifically selected as the first post-
screening experiment for several reasons. The paucity of NMDAr-associated 
manipulations in the paradigm suggested a gap in the literature, allowing this experiment 
both to advance our compounds of interest (potentially) as well as contribute to the 
rapidly growing base of DID knowledge. Furthermore, since acamprosate has 
demonstrated efficacy under standardized DID conditions (Gupta et al., 2008), the model 
appears to possess predictive validity which was notably lacking from our initial DID 
screens. Experiment 8 analyzed a range of doses for both compounds, and adhered more 
rigidly to established DID methodologies.  
 
DID (Model) Subjects 
Mice (n=28; Jackson Laboratory, Bar Harbor, ME) arrived at 15 wks of age, and 
were left undisturbed for 7 days prior to testing. A reverse light:dark cycle was again 
employed, with lights turned on at 2100 h and off at 900 h.  
 
DID (Model) Procedure 
 Animals were habituated, housed and handled as previously detailed. Procedures 
for Experiment 8 differed in that only one week (4 days, total) of ETOH access was given 
prior to the first week of treatments. Additionally, the treatment schedule was varied, 
however as in Experiment 6, all animals received all doses of each compounds, in a 
within-subjects, latin-square design (see Figures 38 & 39). Finally, a 3 hr delay (Rhodes 
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et al., 2005) between ETOH access and initiation of the dark cycle was used (vs. 4 hr in 
screening). 
Figure 38. Latin-Square Treatment Design (Weeks 1-2: 0, 5, 10, 20 mg/kg CP;  
Weeks 3-4: 0, 5, 10, 20 mg/kg JR) 
 
Pre-treatment Drinking: The water bottles were replaced with cylinders containing 20% 
ethanol, which remained undisturbed for 4 hours, after which consumption was recorded 
and water bottles returned. Habituation lasted for one week (4 days of ETOH access). 
Week 1 & 2:  Methods were identical to habituation drinking, with the addition of 
injections (0, 5, 10, 20 mg/kg, ip) of CP-101,606 on treatment days, given immediately 
prior to ETOH access.  
Week 3 & 4:
  
  Methods were identical to habituation drinking, with the addition of 
injections (0, 5, 10, 20 mg/kg, ip) of JR-220 on treatment days, given immediately prior 
to ETOH access. 
115 
 
 
Figure 39. DID ETOH Access Schedule (Single Drug Treatment; Dark/Light Boxes 
Indicate ETOH/Water, Respectively) 
 
DID (Model) Results 
CP significantly reduced ETOH intake, F(1,27)=59.627, p<.001. Paired-samples 
t-tests revealed all doses differed from saline, including 5 t(27)=3.243, p=.003, 10, 
t(27)=7.444, p<.001, and 20 mg/kg, t(27)=6.065, p<.001. These results are depicted in 
Figure 40. 
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Figure 40. Ethanol Consumption Following CP-101,606 Administration 
 
 
JR significantly reduced ETOH intake, F(1,26)=232.346, p<.001. Paired-samples 
t-tests revealed all doses differed from saline, including 5 t(26)=6.206, p=.001, 10, 
t(26)=8.986, p<.001, and 20 mg/kg, t(26)=16.103, p<.001. These results are depicted in 
Figure 41. 
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Figure 41.  Ethanol Consumption Following JR-220 Administration 
 
 
 
DID (Model) Discussion 
Results of this experiment were consistent with screening results; CP appeared to 
reduce consumption relative to vehicle at all doses, however, these reductions did not 
appear dose-dependent. JR also reduced consumption, however, consistent with the 
screening results, such reduction appeared dose-dependent, with the 20 mg/kg dose 
drastically reducing intake. These results are also consistent with the observations of 
Rhodes and colleagues (Rhodes, personal communication), who examined JR-220 at 
these doses as well, however this group observed significant reductions in ETOH 
consumption only at the highest (20 mg/kg) dose.  
 The relevance of these results is supported by the relatively recent recognition of 
DID as a powerful preclinical tool for medications development, with a number of 
promising compounds having recently demonstrated reduction in binge-like intake, 
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including baclofen, CRF antagonists, mGLUr antagonists, mecamylamine and lobeline 
(Moore & Boehm, 2009; Sajja & Rahman, 2011; Gupta et al., 2008; Hendrickson, Zhao-
Shea & Tapper, 2009; Sparta et al., 2008). While somewhat surprising that NMDAr 
compounds have remained unexamined, our results serve the dual-purpose of advancing 
the development of CP and JR, as well as further implicating the role of glutamate (in 
general), NMDAr (in particular) and polyamine-sensitive receptor subtypes (specifically) 
in binge-like intake, a behavior which they are not well-recognized for. 
  
Copyright © Ben Lewis 2011 
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Chapter 8. General Discussion 
8.1 Summary of Results 
 Current evidence suggests that JR-220 and CP-101,606 (Haradahira et al., 2002; 
Mott et al., 1998) are both inhibitory modulators of the NMDAr, whose mechanisms of 
action involve interference with polyamine binding. Thus, for numerous reasons 
discussed above, it was hypothesized that both would perform positively in screens 
designed to examine withdrawal symptoms, neurotoxicity, ETOH reinforcement, relapse 
behavior, stress-associated drinking and ETOH-associated cue conditioning (see Figure 
XX, below). Furthermore, based on success in these screens, efficacy in a standardized 
DID model was hypothesized. Our results were consistent with these hypotheses, despite 
the recognitions that CP needs to be examined in additional screens (e.g., ADE) and that 
some findings deserve more thorough re-examination (e.g., reductions in stretched-attend 
posture). 
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Figure 42. Model of Drinking Progression With Experimental Evidence for 
Intervention 
 
  
 Our results suggested that both JR and CP possess neuroprotective potential in an 
in vitro screen using organotypic hippocampal slices withdrawn from ETOH. Consistent 
with this demonstration of in vitro neuroprotection, our behavioral HIC screen 
demonstrated the ability of these compounds to reduce withdrawal-associated convulsive 
behaviors, which are associated with underlying excitotoxic insult and index withdrawal 
severity. Taken together with molecular screens conducted previous to this dissertation, 
and with the results of behavioral data from neonatal studies which used JR and CP as 
neuroprotective interventions during developmental ETOH exposure (Lewis et al., 
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submitted; Wellmann et al., in press), evidence for the neuroprotective potential of both 
compounds is strong. 
Our EPM screen suggested JR’s ability to reduce ETOH-associated cue 
conditioning, although these data should be interpreted carefully, given the potential 
hypoactive and/or anxiolytic effects of JR in this paradigm. Results from the ADE screen 
indicated anti-relapse efficacy. Our restraint-stress screen demonstrated JR’s ability to 
reduce ETOH’s negative reinforcing value, while our DID experiments suggested the 
ability to reduce its positive reinforcing value. Taken together, these results suggest JR’s 
ability to reduce multiple motivational factors contributing to relapse. While full 
screening of CP was not possible, its similar mechanism of action, similar action in HIC 
screening, and positive performance in all DID experiments suggests that it too possesses 
strong potential, however more thorough screening is required. Taken together, the 
performance of these compounds in our screening procedure provides strong evidence 
for both drugs as potential pharmacotherapeutics for alcoholism, and further implicate 
polyamines and NR2B subunits in multiple mechanisms of ETOH consumption and 
withdrawal. 
 
Although these two drugs are thought to have similar mechanisms of action, albeit 
in variable receptor populations, dissociations in their performance were particularly 
interesting. For instance, CP-101 appeared far more potent in the screens for 
neuroprotective potential (OHSC and HICs). Current evidence suggests that NR2B/2B-
containing receptors represent a high-risk subpopulation that is particularly sensitive to 
such insults. However, at equal doses CP’s performance was not distinguishable from 
JR’s in the DID paradigm, suggesting that while NR2B/2B subpopulations appear to 
contribute to this type of drinking behavior, their contribution is shared. A particularly 
interesting, if somewhat puzzling, dissociation in the behavioral effects of these 
compounds involves the bidirectionality of their effects on activity. CP appears to 
increase open-field activity, while JR-220 appears to reduce it. This difference may be 
indicative of the differential contributions of NR2B-containing subpopulations to activity. 
It is possible that antagonism of NR2B/2B stimulates motor activity, while antagonism of 
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a more heterogenous receptor population depresses it. While supported by the 
observation that nonspecific antagonism depresses activity (Ghasemi et al., 2010) the 
lack of clear indication in the literature as to ifenprodil/eliprodil effects on open field 
activity makes this interpretation tentative, at best. An alternate interpretation would 
suggest that one or both compounds may be interacting with unknown and unanticipated 
transmitter systems, the resulting in disrupted activity.  Regardless, such differences 
illustrate the clear need for further investigation of both compounds. 
 
8.2 Clinical Futures 
 This dissertation has used our group’s screening procedure as a hypothesis-testing 
device. Although the screens provide useful data which allows for the constant re-
evaluation and alteration of our underlying hypotheses, their primary utility is the 
discovery and development of novel compounds for eventual clinical use. However, even 
perfect performance throughout the screening hierarchy cannot be taken as evidence of 
the compounds’ ability to clear any of the numerous hurdles involved with progression 
from ‘bench to bedside’. While not the focus of this dissertation, potential future 
difficulties in the advancement of JR-220 (and similar agmatine analogues) are worth 
consideration, and may guide future studies.  
 
Recent estimates suggest that for every one compound receiving FDA approval, 
approximately 10,000 molecules are synthesized in drug discovery programs. Of these 
10,000, roughly 2.5% will advance to preclinical testing and only .05% to Phase I trials. 
That said, it must be noted that while JR-220’s influence on ETOH intake behavior is 
marked, little more than gross toxicity analyses have been performed; none of the 
numerous toxicology screens (e.g., genotoxicity, hemolysis, cardiotoxicity, mitochondrial 
toxicity, reactive metabolite screening, etc.) have been conducted, nor have any ‘ADME’ 
(absorption, distribution, metabolism and excretion) screens. Our application to the NIH 
Rapid Access to Interventional Development (RAID) program, if accepted, will begin 
such examination. If JR-220 survives the significant failure rate associated with such 
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toxicological/kinetic measures and advances to Phase I testing, its chances remain low: 
CNS drugs have a historically low success rate, with roughly 7.5% of Phase 1 trials 
producing marketable compounds. While JR-220 has several advantages which may 
increase these odds, including its similarity to an endogenous molecule (agmatine), and 
its modulatory action at the target (thought to be a self-limiting characteristic in terms of 
toxicity) its chances of advancement to bedside are limited. An objective acceptance of 
the sizeable odds against JR-220’s success is useful to avoid the recognized pitfall of 
“championing” a promising compound which represents a significant amount of invested 
time and money, past the point at which evidence suggests its limited utility. However the 
recognition of such sizeable odds should not be taken as reluctance or reservation to 
continue JR-220’s investigation. Unlike other areas of drug discovery, many of which 
have existing pharmacotherapies with acceptable effectiveness, the success of current 
FDA-approved medications for treating alcohol related disorders has been marginal, at 
best. When considered alongside the number of people affected by alcohol dependence 
issues, the ‘big risk/big reward’ assessment of medications development work in this 
field becomes apparent. Thus, despite probable failure, the cost-benefit analysis of 
continuing to invest in JR-220 and in future medications development endeavors of this 
nature seems clear.  
 
In contrast with JR, CP has already surmounted many of the challenges involved 
in progressing to humans. CP is orally bioavailable (Taylor et al., 2006), and appears 
well-tolerated, with a favorable side-effect profile. However, clinical trials for several 
(non ETOH-related) diseases have revealed only modest effects. A clinical TBI study 
indicated outcome improvements and reductions in mortality rates, however effects were 
only marginally significant (p’s = .07 and .08, respectively; Yurkewicz et al., 2005). A 
clinical Parkinson’s study found CP was effective at reducing levodopa-induced 
dyskinesia effects, but not Parkinsonism itself (Nutt et al., 2008). Interestingly, it appears 
to produce antidepressant effects in patients unresponsive to serotonin selective reuptake 
inhibitors (Skolnick et al., 2009). However, interest in the compound appears to be 
decreasing; pubmed searches indicated 15 publications related to CP during 2004-2005 
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(at the time when our group noted the compound and began examining it in FASD 
experiments), however only 5 five were noted from 2010 to the current date, all of which 
utilize it as a pharmacological tool in preclinical examinations. Such loss of interest may 
reflect clinical shortcomings of CP, but may also be related to the recognition that CP 
shares discriminative stimuli with phencyclidine; it is self-administered in non-human 
primates who were experienced with PCP administration (Nicholson et al., 2007), 
consistent with observations that CP is dose-dependently associated with dissociative and 
amnestic effects (Nutt et al., 2008). 
 
 The current work is focused specifically on alcoholism and alcohol-related 
effects, however, as the aforementioned  investigations of CP indicate, NMDAr 
modulators are implicated as potential pharmacotherapeutics for a startlingly large 
number of conditions, including chronic pain, Huntington’s, Parkinson’s, migraine, major 
depression, stroke/ischemic injury, epilepsy, and others. While speculative, it is not 
unlikely that in the discovery and development of inhibitory modulators for alcohol 
dependence, compounds with utility in some, if not many, of these additional disorders 
may be produced. An alternate future for these compounds, mentioned only briefly in the 
introduction, involves neuroprotection from ETOH insult in utero, and in particular, from 
the prolonged withdrawal following birth. No pharmacotherapeutic intervention is 
currently available for FASDs, which are thought to involve similar if not identical 
excitotoxic mechanisms as those presented here, providing yet another potential avenue 
of JR-220 development.  
 
 Though not explicitly stated thus far, one potential contribution of the current 
work may not include either compound, but rather the demonstration of this type of 
project’s utility. JR’s transition from simple molecular screening to success in a strong 
preclinical model (the majority of which is contained herein) provides evidence that a 
small research team can accomplish this type of directed drug discovery and 
development. Furthermore, our inclusion of CP in various screens demonstrates the 
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flexibility of the program, which allows for both ‘bottom-up’ examination of novel 
compounds, as well as ‘top-down’ testing of known compounds. 
 
Finally, while this dissertation represents only one of the first few steps toward 
the potential clinical development of these compounds,  our results provide strong 
evidence for both drugs as potential pharmacotherapies, further implicate polyamines and 
NR2B subunits as critical mechanisms in ETOH consumption and withdrawal and 
demonstrate the utility of academic drug discovery and development programs.   
Copyright © Ben Lewis 2011 
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Appendix A: Table Legend 
 
Table 1. Species/Strain Use by Experiment 
Table 2. JR-220 Treatments & Subjects 
Experiments with JR utilized six litters (N=217), distributed across 20 treatment groups. These included 
Control (n=23), ETOH (n=22), Control + 20N (n=18), ETOH + 20n (n=19), Control + MK (n=18), ETOH 
+ MK (n=20), Control + 50 μM JR (n=8), Control + 60 μM JR (n=7), Control + 75 μM JR (n=16), Control 
+ 80 μM JR (n=4), Control + 90 μM JR (n=3) Control + 100 μM JR (n=4), Control + 125 μM JR (n=4), 
ETOH + 50 μM JR (n=7), ETOH + 60 μM JR (n=8), ETOH + 75 μM JR (n=18), ETOH + 80 μM JR (n=3), 
ETOH + 90 μM JR (n=4), ETOH + 100 μM JR (n=4) and ETOH + 125 μM JR (n=6).  
Table 3. CP-101 Treatments & Subjects 
Experiments with CP utilized five litters (N=177), distributed across 16 treatment groups. These included 
Control (n=21), ETOH (n=21), Control + 20N (n=12), ETOH + 20N (n=12), Control + MK (n=12), ETOH 
+ MK (n=12), Control + 5 nM CP (n=6), Control + 10 nM CP (n=10), Control + 25 nM CP (n=12), Control 
+ 50 nM CP (n=12), Control + 75 nM CP (n=4), ETOH + 5 nM CP (n=6), ETOH + 10 nM CP (n=9), 
ETOH + 25 nM CP (n=12), ETOH + 50 nM CP (n=12) and ETOH + 75 nM CP (n=4).  
Table 4. Handling-Induced Convulsion Assessment Scale 
Adapted/modified from Wilson & Little, 1998. 
Table 5. Sucrose Fading Schedule 
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Appendix B: Figure Legend 
 
Figure 1. Simplified Polyamine Biosynthesis (adapted from Coffino, 2001) 
Figure 2. Contributions of ETOH Withdrawal to Reinforcement and Cue Salience 
Figure 3. Molecular Structure of Ifenprodil and its Analogue, CP-101,606 
Figure 4. Molecular Structure of Agmatine and its Analogue, JR-220 
Figure 5. Treatment Distribution Within a Single Culture 
Figure 6. JR-220 in CA1 
PI florescence, by group mean + S.E.M, in CA1 of organotypic hippocampal slice cultures. Data collapsed 
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. * 
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOH-
naïve control group.  
Figure 7. JR-220 in CA3 
PI florescence, by group mean + S.E.M, in CA3 of organotypic hippocampal slice cultures. Data collapsed 
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. * 
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOH-
naïve control group.  
Figure 8. JR-220 in DG 
PI florescence, by group mean + S.E.M, in DG of organotypic hippocampal slice cultures. Data collapsed 
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. * 
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOH-
naïve control group.  
Figure 9. CP-101,606 in CA1 
PI florescence, by group mean + S.E.M, in CA1 of organotypic hippocampal slice cultures. Data collapsed 
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. * 
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOH-
naïve control group. 
Figure 10. CP-101 in CA3 
PI florescence, by group mean + S.E.M, in CA3 of organotypic hippocampal slice cultures. Data collapsed 
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence * 
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOH-
naïve control group. 
Figure 11. CP-101 in DG 
PI florescence, by group mean (+S.E.M.), in CA3 of organotypic hippocampal slice cultures. Data 
collapsed across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. 
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* indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOH-
naïve control group. 
Figure 12. Representative Slices From Select Treatment Groups 
Including Control (a), ETOH (b), 20 μM NMDA (c), 50 μM JR-220 (d), 25 nM CP-101 (e), and 20 μM 
MK-801 (f). 
Figure 13. BEC as a Function of Time and 4MP Treatment 
Blood ethanol content, presented as mean (±S.E.M.) mg/dl, following 2.5 g/kg ETOH administration. 
Groups included 4MP (9 mg/kg) and control. * indicates significance (p<.05) between groups.  
Figure 14. JR-220 HICs, Percent Control Values 
Handling Induced Convulsion scores, presented as mean (+S.E.M.) percentage of ETOH-naïve scores. * 
indicates significance (p<.05) relative to drug-naïve (0 mg/kg) group. 
Figure 15. CP-101,606 in HICs, Percant Control Values 
Handling Induced Convulsion scores, presented as mean (+S.E.M.) percentage of ETOH-naïve scores. * 
indicates significance (p<.05) relative to drug-naïve (0 mg/kg) group. 
Figure 16. Stretched-Attend Behaviors 
Stretched-attend postures, presented as mean (+S.E.M.). Groups included ETOH-treated and ETOH-naïve 
animals, treatments included saline and 20 mg/kg JR-220. * indicates significance (p<.05) between 
treatment conditions. 
Figure 17. Time Spent in Closed vs. Open arms 
Time in open and closed arms, respectively, presented by as mean (+S.E.M.) seconds. Groups included 
ETOH-treated and ETOH-naïve animals, treatments included saline and 20 mg/kg JR-220. * indicates 
significance (p<.05) between treatment conditions. 
Figure 18. Total Arm Entries 
Arm entries (open and closed), presented as mean (+S.E.M.) entries. Groups included ETOH-treated and 
ETOH-naïve animals, treatments included saline and 20 mg/kg JR-220. * indicates significance (p<.05) 
between treatment conditions. 
Figure 19. 20 mg/kg JR in ADE 
ETOH consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily 
mean (+S.E.M.) g/kg. Treatments included vehicle and 20 mg/kg JR-220. * indicates significance (p<.05) 
relative to baseline consumption. 
Figure 20. Water consumption in ADE reinstatement phases (20 mg/kg) 
Water consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily 
mean (+S.E.M.) g/kg. Treatments included vehicle and 20 mg/kg JR-220. * indicates significance (p<.05) 
relative to baseline consumption. 
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Figure 21. 10 mg/kg JR-220 in ADE 
ETOH consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily 
mean (+S.E.M.) g/kg. Treatments included vehicle and 10 mg/kg JR-220. * indicates significance (p<.05) 
relative to baseline consumption. 
Figure 22. Water Consumption during ADE reinstatement phases (10 mg/kg) 
Water consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily 
mean (+S.E.M.) g/kg. Treatments included vehicle and 10 mg/kg JR-220. * indicates significance (p<.05) 
relative to baseline consumption. 
Figure 23. Restrained vs. Unrestrained Drinking 
ETOH consumption, presented as mean (±S.E.M.) g/kg. Treatments included restraint-stress and control 
handling. * indicates significance (p<.05) between treatments. 
Figure 24. JR-220 Treatment (Following 5-day Restraint Period) 
ETOH consumption among restrained animals, presented as mean (+S.E.M.) g/kg. Treatments included 0, 
10, 20 and 30 mg/kg JR-220. * indicates significantly (p<.05) increased consumption relative to all other 
groups. # indicates significantly (p<.05) reduced consumption relative to all other groups. 
Figure 25. Unrestrained Animals, 0 vs. 30 mg/kg JR 
ETOH consumption among unrestrained animals, presented as mean (±S.E.M.) g/kg. Treatments included 0 
and 30 mg/kg JR-220.  
Figure 26. Latin-Square Design for Screen 1 and Screen 2 
Screen 1: Saline, 10 mg/kg CP, 10 mg/kg JR; Screen 2: Saline, 20 mg/kg JR, 300 mg/kg Acamprosate 
Figure 27. DID ETOH Access Schedule  
Figure 28. Daily DID Consumption (4hr/day) Prior to Treatment Phase 
ETOH consumption during the last three weeks of untreated 4 hr consumption, presented as mean 
(±S.E.M.) g/kg ETOH consumption. 
Figure 29. CP-101,606 (10 mg/kg) and JR-220 (10 mg/kg) in DID 
ETOH consumption during the first DID treatment phase, presented as mean (+S.E.M.) g/kg ETOH 
consumption. Treatments included CP-101 (10 mg/kg), JR-220 (10 mg/kg), and saline. * indicates 
significant (p<.05) difference from vehicle treated drinking. 
Figure 30. JR-220 (20 mg/kg) and Acamprosate (300 mg/kg) in DID 
ETOH consumption during the second DID treatment phase, presented as mean (+S.E.M.) g/kg ETOH 
consumption. Treatments included JR-220 (20 mg/kg), acamprosate (300 mg/kg) and saline.  * indicates 
significant (p<.05) difference from vehicle treated drinking. 
Figure 31a. Open Field Quadrant Crosses (By Block) Following Saline, JR and CP 
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Open field activity among Swiss Webster mice, presented as presented as mean (±S.E.M.) quadrant 
crosses, per 2 min block. Groups includes JR-220 (10 and 40 mg/kg), CP-101 (1 and 20 mg/kg) and saline. 
Figure 31b. Open Field Quadrant Crosses (Total) Following Saline, JR and CP  
Open field activity among Swiss Webster mice, presented as presented as mean (±S.E.M.) total quadrant 
crosses. Groups includes JR-220 (10 and 40 mg/kg), CP-101 (1 and 20 mg/kg) and saline. * indicates 
significant (p<.05) difference relative to saline control. 
Figure 32. Open Field Center Dwell-Time Following Saline, JR and CP Treatment 
Center zone activity among Swiss Webster mice, presented as mean (+S.E.M.) time spent (sec). Groups 
includes JR-220 (10 and 40 mg/kg), CP-101 (1 and 20 mg/kg) and saline. * indicates significant (p<.05) 
difference relative to saline control. 
Figure 33. Activity 30-60 min Following JR-220 Administration (Sprague Dawleys) 
Open field activity among Sprague-Dawley rats, recorded 30 min following drug administration, presented 
as mean (±S.E.M.) distance (cm) in 5 min bins. Treatments included JR-220 (10 and 20 mg/kg) and saline. 
*indicates significant (p<.05) treatment effect, such that activity differed between saline and 20 mg/kg 
treated animals. 
Figure 34. Activity 4-4.5 hr Following JR-220 Administration (Sprague Dawleys) 
Open field activity among Sprague-Dawley rats, recorded 4 hr following drug administration, presented as 
mean (±S.E.M.) distance (cm) in 5 min bins. Treatments included JR-220 (10 and 20 mg/kg) and saline. 
*indicates significant (p<.05) treatment effect, such that activity differed between saline and 20 mg/kg 
treated animals. 
Figure 35. Open Field Quadrant Crosses Following Saline or CP (C57 Mice) 
Open field activity among C57BL/6J mice, presented as mean (±S.E.M.) quadrant crosses in 2 min bins. 
Treatments include 0, 5, 10 or 20 mg/kg CP-101. 
Figure 36. Open Field Quadrant Crosses Following Saline or JR (C57 Mice) 
Open field activity among C57BL/6J mice, presented as mean (±S.E.M.) quadrant crosses in 2 min bins. 
Treatments include 0, 10, 20 or 30 mg/kg JR-220. * indicates significance (p<.05) relative to saline control. 
Figure 37. Open Field Quadrant Crosses (Total) Following Saline, 10, 20, or 30 mg/kg JR  
Open field activity among C57BL/6  mice, presented as presented as mean (±S.E.M.) total quadrant 
crosses. Groups includes 0, 10, 20 and 30 mg/kg doses of JR-220. * indicates a significant (p<.05) 
difference relative to all other groups. 
Figure 38. Latin Square Treatment Design 
Weeks 1-2: 0, 5, 10, 20 mg/kg CP; Weeks 3-4: 0, 5, 10, 20 mg/kg JR 
Figure 39. DID ETOH Access Schedule 
Figure 40. Ethanol Consumption Following CP-101,606 Administrationin 
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ETOH consumption during the first DID treatment phase, presented as mean (+S.E.M.) ETOH 
consumption (mL), following injections of 0, 5, 10, and 20 mg/kg CP-101,606. * indicates significant 
(p<.05) difference from vehicle treated drinking. 
Figure 41.  Ethanol Consumption Following JR-220 Administration 
ETOH consumption during the first DID treatment phase, presented as mean (+S.E.M.) ETOH 
consumption (mL), following injections of 0, 5, 10, and 20 mg/kg JR-220. * indicates significant (p<.05) 
difference from vehicle treated drinking. 
Figure 42. Model of Relapse Progression with Experimental Evidence for Intervention 
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